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Abstract
Utilizing the coughing rat model of pertussis to improve vaccine efficacy.
Jesse Michael Hall

Pertussis, also known as whooping cough, is a respiratory disease caused by the highly
contagious, Gram-negative pathogen Bordetella pertussis (Bp). Infection occurs through
inhalation of aerosolized droplets containing Bp, which then colonizes ciliated epithelial
cells of the respiratory tract. Here, Bp expresses toxins and virulence factors that lead to
leukocyte recruitment, paroxysmal cough, and impairment of host innate responses.
Currently, in developed countries, acellular pertussis vaccines (aP; DTaP; Tdap) are used
to prevent Bp infection and whooping cough disease. However, we currently realize that
the aP vaccine efficacy quickly wanes resulting in a reemergence of pertussis. Recent
work performed by the CDC illustrates that current strains are genetically divergent from
the strains originally used to formulate the aP, which may be partially responsible for the
short-lived aP immunity. In an effort to evaluate pathogenesis of recent circulating strains
and, in turn, improve vaccine efficacy, an animal model that recapitulates clinical
manifestations of pertussis is necessary. First, we reintroduced the coughing rat model
of pertussis by comparing two genetically divergent strains, Tohama 1 and recent isolate
D420. Seven-week-old Sprague-Dawley rats were intranasally (IN) challenged with 108
viable CFUs. We measured the hallmark signs of pertussis disease such as neutrophilia,
pulmonary inflammation, paroxysmal cough using whole body plethysmography (WBP),
bacterial burden of the respiratory tract and characterized the serological response to
known virulence factors. Overall, rats infected with D420 had an increase in bacterial

burden in the lung and nasal cavity, an increase in coughs over the course of infection,
and an increase in anti-Bp IgM antibody titers compared to Tohama 1 challenged rats.
The coughing rat model of pertussis can further be used as a preclinical tool to evaluate
vaccine efficacy, as they are more feasible than baboons while still demonstrating
classical manifestations of the disease. Next, we evaluated vaccine mediated immunity
induced through IN and oral gavage (OG) vaccination of DTaP in the coughing rat model
of pertussis, compared to intramuscular (IM)-whole cell pertussis (wP) and IM-aP
immunized rats. Following vaccination, rats were similarly IN infected with 108 CFUs of
Bp strain D420, cough, bacterial burden, respiratory distress, and both systemic and
mucosal serological responses were analyzed over the nine-day infection. Our data show
that both IN and OG vaccination protected against Bp colonization in the respiratory tract
and Bp induced cough, similarly to IM-wP and IM-aP vaccinated rats. IN-aP and OG-aP
vaccination also resulted in the production of anti-Bp IgG antibody titers at day 9 postchallenge; additionally, IN-aP vaccination induced mucosal anti-Bp IgA antibodies in the
nasal cavity. Histology confirmed that both IN-aP and OG-aP immunization protected
against acute inflammation in the lung. Altogether, these data further support that
mucosal vaccination can generate a protective immune response against pertussis.
Furthermore, the coughing rat model of pertussis can be used to improve our
understanding of Bp pathogenesis and can be used to evaluate the “next generation” of
pertussis vaccines.
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Chapter 1. Introduction

1

1.1

Bordetella pertussis overview

Pertussis is a respiratory disease caused by the Gram-negative pathogen Bordetella
pertussis (Bp) (1). Pertussis, also known as whooping cough, was originally reported
during the 15th century in Persia (2). Patients with pertussis were often described as if
they were being strangled without the capacity to expel the irritants in the lung causing
the infection, simultaneously being incapable of inspiration (2). Paroxysmal coughing
occurs so violently that blood can be expelled from the nose and mouth (2). It was not
until 1906 that Jules Bordet and Octave Gengou were able to culture Bp in vitro (3).
Bordet-Gengou (BG) agar was created as a defined medium for the isolation of Bp, and
it consists of glycerine, potato starch, blood, and agar (4). Potato starch is the critical
component of BG, as fatty acids have been shown to inhibit Bp growth, and the starch
works to sequester the fatty acids not only produced by Bp, but from the sputum and
nasal secretion of patients (3).

Bp is a respiratory pathogen that exclusively infects humans, particularly infants (5).
Transmission of Bp occurs through the aerosolization of respiratory droplets containing
Bp (6). Once inhaled, Bp adheres to the epithelial cells of the respiratory tract (7–9). In
humans, incubation of Bp is on average is approximately 7-21 days, and Bp infection can
be broken down into three separate phases: catarrhal, paroxysmal, and convalescent
(10). During the catarrhal phase of pertussis, mild symptoms ensue reflective of a
common upper respiratory tract infection (11). Symptoms include rhinorrhea, sneezing,
anorexia, and a cough that increases in severity and frequency as the infection
progresses (11). One week following the first signs of illness, the patient then enters the
paroxysmal phase, which is characterized by paroxysmal coughing lasting upward of one
2

to four weeks (11). The Centers for Disease Control (CDC) defines paroxysms as multiple
rapid, violent coughs followed by the classical whoop sound associated with pertussis, as
a result of hurried and forced inspiration of air into the lungs (12). Along with the
paroxysms; vomiting, exhaustion, uncontrolled mucus production, increase in white blood
cell count (lymphocytosis and leukocytosis), bronchopneumonia, hypoxia, and choking
can occur in infants (13). Four to six weeks following the onset of pertussis, the patient
will enter the convalescent phase, where paroxysms begin to diminish; however,
nonparoxysmal coughing can persist several months following infection (11). Macrolides
are the standard treatment currently used to treat patients with pertussis. A fourteen-day
round of erythromycin is recommended, azithromycin and clarithromycin have also been
used (14). However, recently in China macrolide resistant Bp has emerged (15). In severe
cases, pertussis can be fatal (0.1% of pertussis cases from 2000-2016) especially in
unvaccinated infants (16). It is estimated there are 24.1 million cases of pertussis
worldwide contributing to about 160,700 deaths every year in children < 5 years of age
(17).

1.2

Pathogenesis

Animal models of pertussis have been instrumental in our limited understanding of Bp
pathogenesis. As highlighted above, Bp is transmitted via the inhalation of respiratory
droplets containing Bp from an infected host (6, 18). Upon entering the host, regulation
of virulence factors is controlled via the master virulence regulator, bvgAS, which is a
two-component signal transduction system (19–21). The sensor kinase bvgS is activated
resulting in the phosphorylation of the response regulator, bvgA (22). Phosphorylation of
bvgA and bvgS activation, commonly referred to as the bvg+ phase, leads to the
3

expression of virulence associated genes (vags) such as pertussis toxin (PT), filamentous
hemagglutinin (FHA), fimbriae (Fim), and adenylate cyclase toxin (ACT) as well as the
repression of virulence repressed genes (vrgs) (22–26).

Upon inhalation, Bp uses adhesins such as FHA and Fim to attached to the ciliated
epithelium of the respiratory tract (22). The autotransporter pertactin (PRN) has been
suggested to play a role in initial attachment of Bp, as PRN contains Arg-Gly-Asp motifs,
which have been shown to play a role in epithelial binding (27). FHA is 232-kDa hairpinshaped protein that is expressed on the outer membrane of all Bordetella spp. Data from
animal models have shown that FHA is crucial for Bp attachment and is highly
immunogenic (13, 28). Proteomic analysis has suggested that FHA is one of the most
abundant proteins of Bp (29). Bp lacking FHA have shown to have diminished capacity
for colonization of the trachea (30, 31). Fim, which are filamentous in structure, are
expressed on the cell surface and have been shown to be required for tracheal
colonization (32). Fim negative strains have shown decreased capacity for bacterial
attachment in vitro, and in vivo; additionally, Fim negative strains had reduced growth in
the upper respiratory tract in mice (32, 33). Bp has 6 serotypes of Fim, with Fim1 being
common amongst all Bp strains while Fim2 has been found on numerous Bp isolates (34).

Once Bp colonization occurs and infection is established, toxins are then released, the
most notable of which is PT. PT is an AB5 ADP-ribosylating toxin that is released and
disseminated systemically (35). PT consist of 6 polypeptides from S1 to S5 subunits; S1
designates the enzymatically active A subunit of PT, while S2, S3, S4, and S5 comprise

4

the B subunit (36–39). The S2-S5 subunits form a pentamer that binds to glycoproteins
on eukaryotic cell membrane surfaces delivering the A subunit (36–39). In the cytoplasm,
ADP-ribosylation of Gi proteins occur rendering them inert (40, 41). This leads to an
increase in cytosolic cAMP and dysregulation of Gi protein signaling. The resulting effect
leads to the dysregulation of innate immune cells particularly neutrophil and macrophage
recruitment to the site of infection (40, 41). PT has also been shown to aid in adherence
during colonization. Morse et al (1976) demonstrate that PT also causes leukocytosis
during infection (42). Other studies have shown that PT can increase sensitivity to
histamines, bradykinin, and serotonin (43).

ACT is also regulated by bvgAS and is secreted during infection. ACT is comprised of an
adenylate cyclase (AC) domain and a repeat in toxin domain (RTX) linked with a
hydrophobic domain responsible for pore formation (44–48). ACT remains localized, as
most of the ACT remains associated with FHA on the bacterial surface, and secreted ACT
quickly forms aggregates in solution rendering it inactive (49, 50). Upon secretion, ACT
binds phagocytic cells via the 𝛼M𝛽2 integrin or CR3 receptor (51). Once bound, the AC
domain is translocated into the cell where it can bind calmodulin to catalyze cAMP from
ATP, resulting in the dysregulation of cellular signaling pathways (52). Most notably,
cAMP formation results in the inhibition of antigen presentation by antigen presenting
cells and induces apoptosis (53–55). ACT activity in macrophages results in membrane
ruffling, cytoskeleton rearrangement, and loss of complement-mediated phagocytosis
(56).

5

Other virulence factors associated with Bp include dermonecrotic toxin, tracheal
cytotoxin, and lipopolysaccharide (LPS) (57). Dermonecrotic toxin is a heat-labile toxin
that causes necrotic lesions, and intravenous administration of dermonecrotic toxin is
lethal in mice (58, 59). Tracheal cytotoxin is a disaccharide-tetrapeptide and during
infection, tracheal cytotoxin leads to damage of the ciliated epithelial cells of the
respiratory mucosa (57). LPS of Bp lacks the O antigen and it is referred to as
lipooligosaccharide (LOS), which is extremely immunogenic; and O antigen negative
mutants are attenuated during infection (22).
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Table 1. Bordetella virulence associated genes. +/- annotates expression in select strains
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1.3

Pertussis vaccines

In the pre-vaccine, era the number of pertussis cases ranged from 150,000-200,000
cases in the United States annually (Fig. 1) (59). After the in vitro culture of Bp, the
development of whole-cell pertussis vaccines (wP) immediately ensued. The first licensed
wP was made from aliquots of killed Bp in 1914 (60). It was not until 1948 that wP was
combined with diphtheria and tetanus toxoids creating the Diphtheria Tetanus Pertussis
vaccine (DTP) (11, 61, 62). Widespread use of DTP in the United States led to a 90%
decrease in the number of reported Bp infections (63). After implementation of the DTP,
the number of pertussis cases in the Unites States was < 1,000-5,000 cases between
1970-1980 (Fig. 1) (59). With the decrease in number of pertussis cases, it was
hypothesized the disease was eradicated (64). Despite the efficacy of this vaccine,
serious adverse side-effects ensued including swelling and redness at the injection site,
fever, and uncontrollable crying of infants (65). In rare instances, vaccine-induced
encephalopathy was reported following DTP immunization (66). Due to these side-effects,
patient compliance regarding DTP vaccination decreased, particularly in Britain, Japan,
and United States (11). After two infant mortalities were reported following DTP
immunization, the Japanese Ministry of Health and Welfare formed the Pertussis Vaccine
Study Group for the development of a safer and effective acellular pertussis vaccine (aP,
DTaP, Tdap) in 1981 (67). Low to middle income countries still use DTP vaccines today
to protect against pertussis.

8

It was not until 1984 that Sato and Sato developed the first aP in Japan, which consisted
of formaldehyde treated FHA and formalin treated PT (67). Vaccination with the newly
developed aP was protective in children over the age of 2 years old (68). A subsequent

Reported pertussis cases
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DTP-vaccine era
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Figure 1: Reported pertussis incidence in the United States from 1922-2019.
Adapted from the CDC.
vaccination study also confirmed that the aP was less reactogenic than the wP, despite
being protective and generating a serological response to the vaccine antigens (69).
During the development of the aP, 13 antigens were originally selected for testing (70).
The antigens that were selected to be included in the aPs were FHA, Fim, PT, and PRN,
as each one of these antigens were immunogenic, providing a serological response after
vaccination and playing a role in Bp pathogenesis (70). ACT was thoughtfully considered
to be included, but with the limited research surrounding ACT at the time and the limited
availability of a purified product, ACT was left out of aP formulations. It was not until 1996
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that DTaP was licensed for use in infants in the United States. One year later, the Advisory
Committee on Immunization Practices (ACIP) recommended DTaP vaccination over DTP
vaccination in infants. It was not until 2006, that the ACIP recommended that a Tdap
booster vaccine be administered during adolescence.

1.4

Waning efficacy of the current acellular vaccine

After the switch from the DTP to DTaP, there has been a significant increase in the
number of pertussis cases, especially in the United States (71) (Fig. 1). While nationwide
vaccine coverage is 95% in the United States, the incidence of pertussis has risen in the
past 10 years as the number of only DTaP vaccinated individuals has increased in size.
(72). Studies suggest that four years after a patient’s last DTaP vaccination, the induced
vaccine efficacy is only nine percent, which is unacceptable vaccine protection (5). While
vaccine coverage remains high, the population dynamics are changing, and more people
are DTaP immunized as new generations are born and the DTP immunized only
generations age. Numerous studies have demonstrated waning efficacy following DTaP
vaccination in parallel with the emergence of genetically divergent strains of Bp (73–79).
Increased surveillance of Bp has led to the identification of clinical isolates that do not
express PRN, FIM, and even PT, the hallmark toxin of the organism (80). Research has
shown that PRN mutant strains have been present since the 1990s, while only 15% of
isolates express PRN currently (81). Bp is evolving to not express the proteins that are
found in the current aP (80). One plausible hypothesis to explain these observations is
that circulating Bp strains have evolved due to aP vaccine pressure. Vaccine-driven
evolution of Bp could contribute to the waning efficacy of the aP. While we know the
current strains are genetically different, we do not know if this genetic variability affects
10

virulence, disease burden, toxicity, or fitness of the pathogen (79). With that said, it is
imperative to find a means to increase the efficacy of the current pertussis vaccines.

1.5

Recent Evolution of Bp

Since the introduction of DTaP in 1996, the Bordetella research community has observed
cyclic increases in the reported number of pertussis cases caused by the bacterium Bp
(82). Current surveillance of Bp in the United States has identified genetic changes
alongside the reemergence of pertussis (83, 84). This is highly alarming as Bp is naturally
considered to be a monomorphic pathogen (85). Recent clinical isolates have been
identified that are deficient in either FHA, PRN, and PT, which are components of the aP,
despite adequate vaccine coverage (86–89). New data generated by the CDC highlights
the genetic divergence of current circulating strains of pertussis from the reference strains
that originally helped to produce the vaccine (83). The clinical isolates differ due the
presence of SNPs and chromosomal rearrangements which could contribute to the
pathogen’s overall fitness and ability to infect. It is essential to critically evaluate the
significance of the evolution of these strains and their potential disease burden.

1.6

Animal models of pertussis

Bp is exclusively a human respiratory pathogen, and as a result, a diverse repertoire of
animal models have been used. The evolution of animal models of pertussis has been
fundamental in our understanding of Bp pathogenesis and the formulation of vaccines
against this pathogen. Robust efforts have been made to develop animal models capable
of recapitulating pertussis as seen in humans. Currently, mice have been widely accepted
and are used to study pertussis, in addition to non-human primates, piglets, and rats.
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Cost, accessibility of reagents, and genetic manipulation also contribute to the feasibility
of mice as a model of pertussis.

Mice infected with Bp develop leukocytosis, hyperinsulinemia, histamine sensitization,
and comparable respiratory infection to humans (90). In mice, three different routes of Bp
challenge have been explored: intracerebral (IC), intranasal (IN), and through aerosol
exposure. These routes of Bp challenge were selected as Bp can only grow in the
respiratory tract or the brain of mice (11). In 1947, Pearl Kendrick and Grace Eldering
developed the IC mouse model to assess wP vaccine efficacy, as the pertussis
community at the time needed a way to test pertussis vaccine potency (91). IC Bp
challenge in mice was considered the gold standard for testing wP vaccine potency at the
time, as results correlated to similar vaccine potency tests in field trials by the Medical
Research Council (92). In short, mice were intraperitoneally (IP) vaccinated with wP,
followed by a subsequent 105 CFU IC Bp challenge at 14 days post-vaccination (91).
Vaccine efficacy was determined by the survival of the mouse (91). After development of
the aP, IC challenge model in mice failed to predict aP vaccine efficacy; however, the IN
Bp challenge model was successful at evaluating aP vaccine efficacy (93). Vaccine
efficacy was then determined not solely on survival of the mouse, but also the serological
response to vaccine antigens and bacterial clearance in the respiratory tract (93). Aerosol
challenge of Bp was investigated as IN Bp challenges rely on depositing large bacterial
loads into the lungs of mice rather than uniform bacterial placement in the respiratory tract
(22). Aerosol challenge resulted in a more uniform respiratory tract infection compared to
IN Bp challenge (94). Intraperitoneal challenge of Bp in mice was also investigated as a
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potential method for challenge; however, Bp did not readily colonize in the peritoneal
cavity (95). Limitations of the mouse model of pertussis include the absence of a
paroxysmal cough, reproducible pertussis pneumonia, transmission, and limited nasal
colonization (22).

Piglets have also been used as an animal model to study pertussis (96–99). In 2005,
Elahi et al demonstrated that 4-week-old piglets can be infected from intrapulmonary
inoculation of Bp (96). Bp challenged piglets display nonparoxysmal coughs, labored
breathing, nasal discharge, and fever (96). Following challenge, all piglets developed
bronchopneumonia, and histology confirmed pulmonary inflammation of neutrophils and
macrophages in the airway (96). One caveat of the pig model of pertussis is that pigs
older than five weeks of age are not readily infected following Bp challenge (97). This
phenomenon is observed as the peptide beta-defensin 1 is present in the upper
respiratory tract after five weeks of age and protects against Bp challenge (98). The pig
model of pertussis has demonstrated that maternal immunization confers protection to
offspring following vaccination (99). Pregnant sows were vaccinated with heat inactivated
Bp and their newborn piglets fed from their mothers for approximately 5 days followed by
subsequent Bp challenge (99). Newborn piglets were protected against marked
pathological changes and bacterial burden in the respiratory tract (99).

Besides rats, nonhuman primates are the only other known model of pertussis that share
similar coughing manifestation following Bp challenge (100, 101). IN inoculation of Bp in
nonhuman primates results in lymphocytosis, leukocytosis, and transmission of Bp (101–
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106). Recently, Warfel et al (2012) evaluated baboons as a potential pertussis animal
model. Olive baboons were selected as they have similar body temperatures to humans
(101). Baboons IN challenged with 1010 CFU of Bp resulted in cough, bacterial
colonization, and leukocytosis (101). Warfel et al (2014) also showed that aP vaccinated
baboons were protected against pertussis disease following subsequent Bp challenge;
however, they were not protected against bacterial colonization and transmitted Bp to
unvaccinated baboons (107). wP immunized and convalescent baboons rapidly cleared
the infection following Bp challenge (107). Protection afforded by the aP was suggested
to be a more Th2-skewed immune response, while wP and convalescent immunity
induces a mix of Th1 and Th17 immune responses (107–109). These data illustrate that
the immune response generated by aP vaccination protects against pertussis disease but
fails at protecting against Bp transmission to an unvaccinated host; however, the Th1 and
Th17 immune response generated by wP and prior infection prevents colonization and
the subsequent transmission of Bp (107). More recently, rhesus macaques have been
used as a nonhuman primate model of pertussis (110). While the nonhuman primate
model of pertussis shares many clinical manifestations of pertussis similar to humans, the
expensive animal cost, limited and specialized facilities, and ease of use limit the use and
availability of this model.

1.7

Coughing rat model of pertussis

The coughing rat model of pertussis was first introduced in 1939, and nine studies in total
have been published using the coughing rat model of pertussis to study Bp pathogenesis
and vaccine-mediated immunity (Table 1). Two separate Bp challenge methods have
been used in the development of the coughing rat model of pertussis. In 1939, Hornibrook
14

and Ashburn IN challenged rats with Bp, as mice were readily infected following IN
challenge of Bp (111). IB inoculation of Bp was not utilized until 1989, which was
developed in part as IB inoculation of Pseudomonas aeruginosa resulted in an respiratory
infection (112). During this time, Hornibrook was also working on developing a
semisynthetic liquid medium for the isolation of soluble antigens (113).
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Date
Intranasal

Inf. Method

Yes

Yes

Bp induced Cough

Acute and
chronic inf.

Histology
of the lung
Acute and
chronic inf.

Yes

Yes

Yes

Yes

Loss of
body wt.

Results
1939

Intrabronchial
Yes

Yes

Total IgE

Loss of
body wt.

Publications

1989
Intrabronchial

Yes

Total IgE

Body wt.
change

1993

Intrabronchial

Yes

Yes

IgG:PT, Bp,
FHA
IgG:
PT, Bp,
FHA, PRN

Total IgE

Bp recovered
from lung

1994

Intrabronchial

Yes

Yes

IgG:PT, FHA

Bp induced Antibody titers

Abbr. Title
Study of Experimental
Pertussis in the Rat

1994

Intrabronchial

Yes

Yes

Leukocytosis/
lymphocytosis

Development of a Rat Model
for Respiratory Infection of
Bp

1997

Intrabronchial

Yes

PT, Bp, FHA

Yes

Yes

Yes

Coughing Rat Model of
Pertussis* (Pertussis report)

1998

Intrabronchial

Yes

Lung Wt.

Loss of
body wt.

Cough production,
leucocytosis, and serology of
rats

1999

Intranasal

IgG:PT, Bp ,
FHA
IgG:

Responses to Bp mutant
strains and to vaccination
Differences in Coughing and
other responses to Bp
infection

2019

IgA: PT, FHA

Responses to acellular
pertussis vaccine coughing
rat model
Time-course of infection and
responses in a rat
BspR/BtrA and Anti factor
regulates Bb to cause cough

Table 2. Summary of literature and results using the coughing rat model of pertussis (111-120).

Vaccines
studied

DTP

2-aP, 3-ap,
DTP
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1.7.1 Intranasal challenge
It was first reported in 1939 that young rats developed paroxysmal cough after IN
inoculation of Bp (111). Hornibrook and Ashburn hypothesized that rats could be a
suitable animal model to study pertussis, as mice infected with Bp produced pneumonia
and death following IN challenge (111). To test this hypothesis, 3-week old rats were
intranasally infected with Bp and survival was monitored for up to 10 days post-challenge
(111). Following challenge, approximately 12 percent of Bp infected rats died after two
days post-challenge (Fig. 2) (111). By day 9 post-challenge, 72.5 percent of Bp infected
rats died (Fig. 2) (111). Coughing was recorded for 12 of the 51 Bp infected rats, and it
was noted that on average, coughing did not appear until approximately 8 days postchallenge (111). Coughing continued in some rats for up to 60 days post-challenge (111).

Percentage of Bp infected rats

Percent death of 3-week old Bp infected rats
100

Percent dead

80

Percent alive

60
40
20
0

2

3

4

5

6

7

8

9

Days post challenge

Figure 2. Percent death of young Bp infected rats. 3-week old Wistar
albino and hooded rats were intranasally infected with 1.7x108 CFUs
of Bp. Survival was monitored for up to 9 days post-challenge.
Adapted from (Hornibrook and Ashburn, 1939).
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Pathological examination revealed that Bp colonization of the lung resulted in interstitial
bronchopneumonia combined with exudate infiltration into the alveoli (111). By day 3
post-challenge, infiltrating neutrophils accumulated in the lung, followed by monocyte
infiltration by day 6 post-challenge (111). It was not until 2019, that IN inoculation of
Bordetella bronchiceptica (Bb) was used to evaluate mechanisms responsible for Bb
elicited cough (114). In summary, these data revealed that rats can be readily infected
with Bp and infected rats developed cough-like paroxysms similar to humans.

1.7.2 Intrabronchial challenge
To the best of our knowledge, the rat model of pertussis was not used again for almost
50 years. It can be hypothesized that the lack of studies using the coughing rat model of
pertussis was due to the development and implementation and success of DTP (112). As
safety concerns surrounding the DTP emerged, so too did the need for an adequate
animal model to understand the pathogenesis of Bp. Significant progress was made, in
parallel, utilizing mice as a challenge model to identify protective aP antigens; however,
mice lacked several aspects of disease as seen in humans: Most notably, Bp induced
cough combined with an upper respiratory tract infection and a repeatable pertussis
elicited pneumonia. Woods et al (1989) decided to utilize IB challenge Sprague-Dawley
rats with Bp encased in agar beads, as this challenge method was successful at
establishing Pseudomonas aeruginosa infection in rats (112). In brief, 107 CFUs of Bp
was added to a mixture of melted 2% agar and heated mineral oil, and rapidly cooled
creating Bp encased agar beads (112). Two hundred adult (~200 gram) Sprague-Dawley
rats were challenged with either Tohama I (virulent) or Tohama III (avirulent) (112).
Tohama I was recovered from the lung for up to 7 days post-challenge, while no infection
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was observed in Tohama III infected rats (112). No morbidity was observed following
challenge (112). Pathological analysis revealed lymphocyte infiltration into the bronchi at
day 3 post-challenge, followed by inflammation of the mucous membranes and
bronchioles by monocytes and polymorphonuclear cells (PMNs) by days 7 and 21 postchallenge (112). It was also noted that intrabronchial challenge of Bp induced a
“paroxysmal like” cough as seen in humans (112). A following study performed by
Wardlaw et al (1993) utilized sound activated tape recorders to detect cough for up to 21
days post challenge (115). Isolated coughs along with multi-cough events, similar to a
paroxysmal cough, were detected (115). Peak numbers of cough were recorded at day
10 post-challenge and an increase in white blood cell counts were also observed over the
21-day infection (115). Hall et al (1994) further confirmed that Bp infected rats developed
paroxysmal cough and leukocytosis (116). The serological response to Bp challenge was
also investigated: Intrabronchial challenged rats developed IgG antibody titers to Bp
sonicate, PT, and FHA at day 28 post-challenge (116). It was not until 1999, that Hall et
al illustrated the unique inverse relationship between bacterial burden and cough (117).
By day 10 post-challenge, as cough counts were the highest, bacterial burden in the lung
was the lowest (117).

With the development of a pertussis model that shared similar coughing manifestations
as humans’, mechanisms responsible for the Bp induced cough were explored. Rats
challenged with Phase 1 (virulent) strains of Bp such as 18-323, Tohama I, and L-84
induced coughing at days 9-14 post-challenge (118). Phase 4 (avirulent) strain L-84
induced no coughing, highlighting that virulence factors are responsible for Bp induced
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cough (118). Bp strain 357 harboring a transposon-insertion in the region encoding for
PT induced no coughing following challenge (118). Similar results were observed in rats
challenged with Bordetella parapertussis, which does not produce PT (118). Although
debated, these results suggest that PT plays a role in the induction of cough during
pertussis infection. Further studies are needed to accurately depict the factor(s) inducing
cough following infection.

Strains of rats were also evaluated in the development of the rat model of pertussis. While
past studies relied on Sprague-Dawley rats to evaluate Bp pathogenesis, Brown Norway,
Lewis, and Hooded Lister rats were also tested (119). Brown Norway, Lewis, Hooded
Lister, and Sprague-Dawley rats all coughed following IB challenge of Bp, although
Sprague-Dawley rats coughed more consistently compared to the other strains (119).
Leukocytosis was observed in all four strains of rats, as high as 4-fold compared to the
non-infected controls (119). Younger, 4-week-old rats had an increased propensity
toward infection as a decrease in weight gain and increase in mortality were observed
compared to 6-week-old rats, regardless of the rat strain (119). Hall et al (1997) further
illustrated that total IgE in the serum of Sprague-Dawley, Brown Norway, Lewis, and
Hooded Lister rats were elevated following Bp challenge (119). Anti-Bp and anti-FHA IgG
antibodies were detected in all rat strains; however, Hooded Lister and Lewis rats did not
develop anti-PT IgG antibody titers post challenge, suggesting host genetics could
possibly play a role (119).
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Limited studies have investigated the vaccine efficacy of DTP and DTaP in the coughing
rat model of pertussis. To measure vaccine efficacy of the DTP, one single human does
was administered IP to 3-week-old Sprague-Dawley rats, followed by subsequent
intrabronchial Bp challenge 3 weeks later (118). DTP vaccination provided protection
against Bp elicited cough compared to mock vaccinated challenged rats (118). DTP
vaccinated rats also developed serum anti-FHA and anti-Bp antibody titers at day 28 post
challenge (118). Hall et al (1998) also confirmed that two 1.5 human doses of Evans’ DTP
administered subcutaneously at 21 and 7 days before challenge protected against cough
upon intrabronchial Bp challenge (120). SmithKline Beecham’s 3-component aP vaccine
containing detoxified PT (PTd), FHA, and a 69kDa antigen (presumably pertactin (PRN))
as well as Connaught;s 5-component containing PTd, FHA, agglutinins 2+3 (fimbriae),
and PRN administered subcutaneously 21 and 7 days before challenge were also
protective against Bp induced cough (120). Both aP vaccines and Evans’ DTP protected
against Bp induced leukocytosis (120). Vaccination with PT, FHA, PRN, and fimbriae
alone with no adjuvant did not significantly protect against cough compared to mock
vaccinated challenged rats (120). These data suggest that vaccination against pertussis
needs to be multi-valent and adjuvanted. Overall, aP and wP vaccines were protective
against Bp induced cough and leukocytosis (120). Protection against bacterial burden in
the coughing rat model of pertussis following vaccination has yet to be established.

In summary, the coughing rat model of pertussis can be used as a tool to not only evaluate
Bp pathogenesis, but also as a preclinical model to investigate vaccine efficacy. The
coughing rat model of pertussis can be utilized to investigate mechanisms responsible for
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coughing during Bp infection, as well as in the validation of new vaccine formulations or
routes of immunization to determine their ability to protect against Bp.

1.8

Natural immunity against Bp

As described above, Bp is a respiratory pathogen. During infection, Bp colonization
remains strictly within respiratory tract, and dissemination is rarely observed during
pertussis infection (13, 121). Both the innate and adaptive immune responses are vital to
recognition and defense against Bp. Only in mice with immunodeficiencies does Bp
disseminate to other organs such as the spleen and liver (122). Recognition of Bp in the
airway induces the infiltration of macrophages, dendritic cells, neutrophils, and NK cells
(123–125).

Macrophages have been shown to play a role in immunity against Bp. In mice, depletion
of macrophages by liposome-encapsulated clodronate in the airway led to an increase in
bacterial burden in the respiratory tract up to 2 weeks post-challenge (126). Macrophage
killing of Bp by nitric oxide has been shown to be increased with supplementation of IFN𝛾 (127, 128). Bp challenge in IFN-𝛾 -/- mice results in dissemination of Bp and mortality
(122, 129). IFN-𝛾 secreting Th1 cells were associated with recovery in children with
pertussis (130, 131). Altogether, these data show that macrophages are essential in
clearance and protection against Bp.

The role of neutrophils in pertussis immunity has been quite a contrast to that of
macrophages. Studies in mice have shown that infiltration of neutrophils occurs as early
as 5 days post-challenge and as late as 14 days post-challenge (132, 133). During naïve
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infection, neutrophils seem to not play a role in the clearance of Bp, presumptuously, due
to the inhibitory function of both PT and ACT (41, 134). PT works by delaying the overall
neutrophil response during the initial stages of infection, and ACT works by dysregulating
neutrophil phagocytic propensity (41, 135). Neutrophils of convalescent mice or mice
receiving sera with opsonizing antibodies toward Bp are capable of antibody-mediated
phagocytosis; suggesting they play a role in Bp clearance in an immune competent host
(41). Neutrophil extracellular traps (NETs) have also been observed during Bp infection
(136).

Induction of adaptive immunity towards Bp is necessary for protection against pertussis.
Both mice and patients previously infected with Bp have measurable amounts of IgA in
their nasal fluids, and Bp specific IgG antibodies in their serum (137). In humans,
passive immunization of Bp specific sera resulted in a decrease in overall disease severity
(138). Patients with an increase in anti-PT and anti-PRN antibody titers had a lower
incidence in pertussis than members of the same house-hold after Bp exposure (139). In
mice, the generation of antibodies following Bp challenge does not result in significant
levels of antibody titers until approximately 1 month post infection, suggesting antibody
responses are not a major player in immunity to a primary infection (137). Immunization
with Bp specific antigens results in the induction of antibody titers to Bp, and passive
immunization results in protection against pertussis (140). Ig -/- mice fail to clear pertussis
infection, eventually developing a chronic respiratory infection; however, the transfer of
Bp immune competent mature B cells was capable of restoring protection against
pertussis (140, 141).
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Cell meditated immune responses have also been shown to play a role in immunity to Bp.
CD4+ T cells specific for PT, FHA, and PRN were isolated from infants following pertussis
infection. The isolated T cells were found to secrete IFN-𝛾, with limited secretion of IL-4
and IL-5, demonstrating that Bp infection induces a Th1 rather than Th2 immune
response (130, 131). Athymic nu/nu mice challenged with Bp resulted in chronic infection
and even death; however, this phenotype was rescued by adoptive transfer of splenic
CD4+ cells but not CD8+ cells (137). CD4+ positive mice isolated from Bp infected mice
secrete Th1/Th17 associated cytokines: IFN-𝛾 and IL-17 (122, 129, 142). IFN-𝛾 -/- and
IL-17 -/- mice challenge with Bp result in an increase in disease severity and bacterial
colonization (142). Additional studies in the nonhuman primate model of pertussis
illustrate that convalescent baboons develop protective Th1 and Th17 immune responses
(108). Taken together, these data conclude that Bp infection induces a protective
Th1/Th17 immune responses.

In summary, protection against pertussis requires both innate and adaptive immune
responses (Fig. 3). Natural infection induces protective Th1/Th17 T cell responses as
well as protective humoral responses. As a result, innate immune cells recruited to the
site of infection can become activated and opsonization of Bp results in antibodymediated phagocytosis.
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Figure 3. Summary of the immunity generated from natural infection. Natural Bp
infection induces both a humoral and effector Th1/Th17 immune response.
Adapted from (Kapil and Merkel, 2019). Created with Biorender.com

1.9

Vaccine mediated immunity

After the resurgence of pertussis, considerable efforts have been made to dissect the
different immune responses induced from either wP or aP vaccination. Recent work in
humans has shown that although DTaP vaccination induces higher IgG antibody titers
compared to DTP vaccinated individuals, vaccine-mediated protection from DTP
immunization lasts considerably longer (143, 144). Further evidence supporting variation
in vaccine-mediated immune response was identified when characterizing the T cell
responses following DTaP and DTP vaccination. Patients receiving DTP vaccination
resulted in a robust Th1 phenotype, while DTaP vaccinated patients presented with a Th2
immune response (145, 146). Studies in mice illustrate that DTP vaccination resembles
similar immune responses to natural infection. DTP immunization induces a robust pro
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inflammatory response, further activating neutrophils’ and macrophages’ ability to clear
Bp from the airway (142, 147, 148). Mice receiving DTP vaccination cleared Bp infection
more readily compared to DTP immunized mice deficient in IFN-𝛾 and IL-17, suggesting
that vaccine-mediated immunity induced by DTP is driven by IFN-𝛾 and IL-17 (140, 142).
Vaccination with DTaP in mice results in a predominant Th2 immune response but also
a Th17 response, likely due to the adjuvant effect of alum. IL-4 -/- mice vaccinated with
DTaP had similar protection to wild-type (WT) mice also vaccinated with DTaP and the
observed protection was mediated by IL-17 (1). In humans, IL-17 mediated protection
induced from DTaP vaccination is absent (142, 149, 150). The antibody responses
following DTP and DTaP vaccination are also different. DTP consists of a diverse
repertoire of antigens, while DTaP consists specifically of 3-5 antigens: PT, FHA, PRN,
Fim2, and Fim3. Primarily the antibody type generated from DTP immunization is IgG2a
while DTaP vaccination results in IgG1 antibodies (1, 142, 149). Warfel et al (2014)
illustrated that DTaP vaccinated baboons were protected from pertussis; however, they
were

not protected against Bp colonization (149). Furthermore, DTaP vaccinated

baboons were capable of transmitting Bp to unvaccinated baboons (149). DTP vaccinated
baboons were protected against Bp burden in the airway (149). These data demonstrate
the clear differences in the generated vaccine-mediated immune responses (Fig. 4).
Taken together with our understanding of convalescent immunity, these data can be used
as a roadmap to an improved DTaP vaccine.

26

Figure 4. Summary of the DTP and DTaP vaccine mediated immunity. DTP
immunization induces both a Th1/Th17 immune response similarly to natural
infection, while DTaP immunization induces more of a Th2 driven immune
response. Adapted from (Higgs, 2012). Created with Biorender.com
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1.10 Mucosal immunization of DTaP
With Bp strictly being a respiratory pathogen, stimulating local immunity at the respiratory
mucosa is critical for the defense against pertussis. Humans previously infected with Bp
develop longer lasting immunity (approximately up to 20 years) (151). On average, the
protective immune response generated from DTaP vaccination is approximately 4-12
years (151). In the nonhuman primate model, convalescent baboons cleared Bp from the
respiratory tract following challenge, while DTaP vaccinated baboons failed to protect
against Bp colonization (149). DTaP immunization induced protection against pertussis
disease, but not bacterial burden, allowing for asymptomatic transmission of Bp to naïve
baboons (149). These data suggest that mucosal immunity is necessary for generating
longer lasting protection against Bp but also in protecting against asymptomatic
transmission of Bp to a naïve host.

Both intranasal (IN) and oral gavage (OG) immunizations have been explored to stimulate
a protective mucosal immune response. In mice, IN administration of DTaP has resulted
in protection against bacterial burden in the respiratory tract (152, 153). As a result, both
anti-Bp and anti-PT IgG antibody titers were induced following IN DTaP vaccination in the
serum, in addition to IgA antibody titers specific to Bp in the lung (152, 153). Wolf et al
(2021) illustrated that the humoral responses elicited from IN DTaP immunization
remained up to 6 months post-vaccination and were protective against bacterial burden
post challenge (153). BPZE1, which is a live attenuated vaccine strain of Bp, has also
been administered IN and has shown to be protective in mice (154). In clinical trials, IN
vaccination of BPZE1 elicits both systemic and mucosal antibody titers specific to Bp
(155). In infants, oral vaccination of wP resulted in the production of mucosal antibody
28

titers in the saliva, as well as systemic Bp specific antibody titers in their sera (156). In a
following study, the frequency of pertussis was lower in newborns for up to one year
following oral vaccination of 1012 CFUs of killed Bp (157). Oral vaccination resulted in
both IgG antibody titers in the serum and IgA titers in the saliva. Studies in mice have
shown that oral vaccination of bacterial vectors (Salmonella typhimurium and Escherichia
coli) expressing FHA elicited anti-FHA titers in the lung (158). These data suggest that
mucosal vaccination can stimulate a protective immune response at the respiratory
mucosa.

1.11 Overall Objective
The objective of this body of work is to build upon the already established coughing rat
model of pertussis and use this model as both a tool and preclinical model to investigate
the efficacy of mucosal immunization with DTaP. As highlighted above, with the
implementation of DTaP vaccines we have seen a resurgence of pertussis, especially in
the United States. Improved animal models combined with improved vaccination
strategies are a necessity to combat pertussis. In chapter 2, the overarching goal was to
further develop the rat model of pertussis that recapitulates the same clinical
manifestations of pertussis in humans. We intranasally challenged rats with reference
strain Tohama 1, which was isolated in 1954 and is one of the most commonly used lab
strains, and strain D420 which is a current representative clinical isolate that was isolated
in 2002 (159, 160). To count coughs and the respiratory profile following challenge, we
utilized whole body plethysmography (WBP). WBP revealed that challenge with D420
resulted in an increase in cough over the twelve-day infection compared to Tohama 1
infected rats. In chapter 3, we utilized the rat model of pertussis to evaluate IN and OG
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immunization of DTaP as a potential mucosal vaccination strategy compared to IM
administration of DTP and DTaP. Our results show that mucosal vaccination of DTaP
through oral and intranasal immunization protects against both bacterial burden and Bp
induced cough. Mucosal vaccination also induced both systemic (IgG) and mucosal (IgA)
antibody titers. In chapter 4, the lessons learned from the coughing rat model of pertussis
and implications/uses of the model are explored, as well as avenues to improve vaccine
efficacy. The work presented here carefully details a preclinical model that can be used
to not only evaluate pathogenesis of Bp, but can be used to test vaccine efficacy. The
data presented further supports that mucosal immunization of DTaP could potentially be
a viable option to improve the current DTaP vaccine efficacy.
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2.1 Abstract
Bordetella pertussis (Bp) is a highly contagious bacterium that is the causative agent of
whooping cough (pertussis). Currently, acellular pertussis vaccines (aP; DTaP; Tdap) are
used to prevent pertussis disease. However, it is clear that the aP vaccine efficacy quickly
wanes, resulting in the re-emergence of pertussis. Furthermore, recent work performed
by the CDC suggest that current circulating strains are genetically distinct from strains of
the past. Emergence of genetically diverging strains combined with waning aP vaccine
efficacy call for re-evaluation of current animal models of pertussis. In this study, we used
the rat model of pertussis to compare two genetically divergent strains Tohama 1 and
D420. We intranasally challenged seven-week-old Sprague-Dawley rats with 108 viable
Tohama 1 and D420 and measured the hallmark signs/symptoms of Bp infection such as
neutrophilia, pulmonary inflammation, and paroxysmal cough using whole body
plethysmography. Onset of cough occurred between 2-4 days after Bp challenge
averaging five coughs per fifteen minutes, with peak coughing occurring at day eight post
infection averaging upward of thirteen coughs per fifteen minutes. However, we observed
an increase of coughs in rats infected with clinical isolate D420 through 12 days post
challenge.

The rats exhibited increased bronchial restriction following Bp infection.

Histology of the lung and flow cytometry confirm both cellular infiltration and pulmonary
inflammation. D420 infection induced higher production of anti-Bp IgM antibodies
compared to Tohama 1 infection. The coughing rat model provides a way of
characterizing disease manifestation differences between Bp strains.
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2.2 Introduction
Whooping cough (pertussis) is a respiratory disease that is caused by the bacterium
Bordetella pertussis (Bp). Pertussis is characterized by severe leukocytosis,
bronchopneumonia, hypoglycemia, and paroxysmal cough (1, 2). During the catarrhal
stage, Bp colonizes the upper respiratory epithelium. Once colonization occurs, Bp
releases toxins such as pertussis toxin (PT), adenylate cyclase toxin (ACT) as well as
others. Following the catarrhal stage is the paroxysmal stage that is characterized by
severe coughing episodes. Innate and adaptive immune responses result in clearance of
the bacterium allowing for the patient or host to convalescence. Despite extensive
research, a full understanding of Bp pathogenesis remains elusive for reasons such as:
vaccine pressure, lack of predictive models, and strain evolution (3). One of the major
reasons for this gap of knowledge is the lack of a suitable animal model that shares
common disease symptoms as seen in humans. Besides non-human primates, rats are
the only other known model of pertussis that share similar coughing manifestation as seen
in humans (4). As of now, the origin or the trigger of cough has yet to be determined (5).
The rat model of pertussis offers a potential animal model that can be used to evaluate
Bp pathogenesis.

In 1938, Hornibrook and Ashburn were the first to report that rats infected with Bp induced
cough-like paroxysms and bronchopneumonia as seen in humans (6). Hornibrook and
Ashburn found that young rats were capable of being infected and the bacterium could
be cultured from the lungs (6). Infected rats produced coughs that could be heard from a
distance of 20 feet (6). Twenty-six of the thirty-one infected rats that did not succumb to
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the infection had pathology indicative of inflammation in the lungs, most notably early
neutrophil infiltration followed by recruitment of mononuclear cells (6). The subsequent
studies utilized intrabronchial inoculation of Bp encased in agar beads and confirmed
leukocytosis and paroxysmal cough by sound activated tape recorders from 5 to 21 days
post challenge (7, 8). Further development of the rat model led to the evaluation of PT
negative strains and the evaluation of coughs (9). Strain BP357, which is deficient in PT
resulted in low cough induction (9). Further evaluation of the rat model demonstrated
leukocytosis, weight loss, and paroxysmal cough in Sprague-Dawley rats during the
course of Bp infection (10). During the development phase of the acellular pertussis
vaccine (aP, DTaP), the rat model was used to test vaccine efficacy of various acellular
pertussis formulations and was used to validate protection against the onset of
leukocytosis and cough (11). Recently, an intranasal rat model has been used to evaluate
bacterial factors responsible for cough in Bordetella bronchiseptica (Bb) (12). BspR
,which is an anti-sigma factor of Bb, plays some role in cough induction upon infection
(12). Collectively, these studies show that the pertussis rat model can be used to critically
evaluate Bp pathogenesis and disease progression.

In the 1940s, whole-cell pertussis (wP and DTP) vaccines were introduced to protect
against Bp infection (13). Widespread use of DTP in the United States led to a 90%
decrease in the number of reported Bp infections (13). Despite the efficacy of this vaccine,
serious adverse side-effects ensued, leading to the development of acellular pertussis
vaccines. The antigens that are included in the current aPs contain: filamentous
hemagglutinin (FHA), fimbriae (FIM), PT, and pertactin (PRN). After the switch from the
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wP to the aPs, there has been a significant increase in the number of pertussis cases in
the US and Europe (14). While nationwide vaccine coverage is 95% in the United States,
the incidence of Bp infections rose in the past 10 years as the number of aP vaccinated
only population has increased in size. (15). While vaccine coverage remains high, the
population dynamics are changing, and more people are aP immunized as the new
generations are born and as the wP only generations age. Numerous studies have
demonstrated waning efficacy of aPs in parallel with the emergence of genetically
divergent strains of Bp (3, 16–21). Increased surveillance of Bp has led to the
identification of clinical isolates that do not express PRN, FIM, and even PT the hallmark
toxin of the organism (22). One plausible hypothesis to explain these observations is that
circulating Bp strains have evolved due to acellular vaccine pressure. While we know the
current strains are genetically different, we do not know if this genetic variability affects
virulence, disease burden, toxicity, or fitness of the pathogen (3).

Early rat studies were performed with intranasal administration of Bp for infection (6).
Subsequent rat challenge studies used Bp encased in agar beads for intrabronchial
instillation (7–11, 23). While the agar bead infection method was successful at
establishing infection, we aimed to utilize the simplicity of intranasal administration. We
sought to re-investigate the coughing rat model of pertussis to compare the pathogenesis
of reference strain Tohama 1 to the recent clinical isolate D420, which has been
extensively studied in the baboon model of pertussis (24–30). Tohama 1 was first isolated
from a case of whooping cough in 1954, while D420 was isolated in 2002 from a critically
ill infant in Texas (25, 31). Although Tohama 1 is now a reference strain that has been
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widely used since Sato and Sato developed the aP but recent data has shown that this
strain is an considered an outlier (32, 33). Tohama 1 does expresses PRN but has lower
expression of PT and ACT (34). When Tohama 1 was used as a challenge strain in
baboons, the baboons did not exhibit symptoms of pertussis despite being infected (26).
This led to the selection of recent clinical isolate D420 as the baboon challenge strain,
which readily infected and caused disease (26). With 48 years of potential genetic
divergence, we sought to understand the differences in pathogenesis between these two
commonly studied strains. D420 is known to infect mice and baboons and it belongs to
the clade (CDC013) of strains that represented 50% of isolates recovered in the US in
2000 (3). However, it is important to note that D420 has an intact pertactin gene and it
does express the PRN protein as confirmed by shotgun proteomic analysis (data not
shown).

In our current study, we aimed to re-establish an upper respiratory tract infection model
in rats following intranasal challenge with Tohama I and D420. We hypothesized that
recent isolate D420 would induce a more severe disease profile compared to Tohama 1,
as previous research investigating pathogenesis in rhesus macaques noted that Tohama
1 infected animals did not exhibit overt disease symptoms (26). Sprague-Dawley rats
were intranasally challenged with Bp and we characterized their disease progression
profile over a twelve-day infection. Cough was critically assessed utilizing whole body
plethysmography (WBP). Bacterial colonization, leukocytosis, and serological responses
were measured as a result of infection. Rats challenged with D420 had increased
coughing, greater bacterial burden in the respiratory tract, and a more robust IgM antibody
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response compared to Tohama 1. The coughing rat model of pertussis can shed light on
the pathogenesis of Bp and will likely be useful tool for pertussis vaccine evaluation.

2.3 Results
D420 infected rats have increase number of coughs compared to strain Tohama 1
over the entire course of infection.
Over the past decade it is became clear that improvements to the acellular pertussis
vaccine strategy are needed due to the rise of PRN mutants, genomic divergence, and
epidemiological data. We believe in order to improve pertussis vaccines we need to better
understand the pathogenesis of Bp in an animal model that shares similar clinical
manifestation of pertussis as seen in humans. Here, we intranasally infected sevenweek-old Sprague Dawley rats with 108 CFU of Bp strain D420 or Tohama 1 (Fig. 5) in
an effort establish infection and observe Bp induced cough. For negative controls (no
bacterial challenge), rats were intranasally administered sterile phosphate buffer saline
(PBS). Paroxysmal cough is the hallmark symptom of pertussis and is thought to play a
major role in transmission of the organism to a new host. To quantify respiratory function
during infection, we utilized whole body plethysmography (WBP). WBP instrumentation
consists of specialized containment chambers which monitor box flow, temperature, and
airflow changes to measure respiratory function. Counting coughs via WBP provides an
extremely accurate and unbiased way of counting coughs based on cough waveforms.
Rat containment chambers were placed inside a laminar flow hood and connected to a
computer that would monitor the rats breathing (Fig. S1). Early studies reported that Bp
infection in young rats induced coughs that were audible by ear (6) and in our preliminary
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studies this was apparent to us as well (data not shown). Studies in the 1990s, of
paroxysmal cough in rats were quantified with an analog sound recording device (7). We
hypothesized that rats infected with recent isolate D420 would induce more coughs than
reference strain Tohama 1, because rhesus macaques infected with Tohama 1 did not
exhibit overt disease symptoms but D420 induced robust coughing in baboons (26). Bp
infected rats developed cough at days 2-11 (Fig. 6B-C), while the mock infected rats (Fig.
6A) only had a few isolated coughs, unrelated to infection. Days 1-3 post infection, the
average cough count of rats infected with Tohama 1 or D420 was less then 5 coughs per
fifteen minutes. The average cough count doubled by day 7 post infection with peak
coughing occurring at day 8 post infection with an average of 13 coughs per fifteen
minutes of monitoring. After day 8, the average cough count for rats infected with D420
remained above 10 coughs per fifteen minutes, while the rats infected with Tohama 1
averaged less then 5 coughs. To summarize the cough data, the average cough count
over the course of infection is shown (Fig. 6D). We observed a significant increase in the
number of coughs at day eight post infection of Bp infected rats compared to the mock
challenge control. Rats infected with D420 coughed a total of 949 times, whereas rats
infected with Tohama 1 coughed a total of 724 times over the entire twelve-day infection.
To analyze differences in cough count between strains, we utilized Area Under the Curve
(AUC) analysis (Fig. 6E). AUC analysis allows us to quantify the number of coughs over
the entire course of infection per rat. Upon this analysis, we note a significant increase in
the number of coughs for rats infected with D420 compared to the mock challenged rats
over the twelve-day infection, while there was no significant difference observed in
Tohama 1 infected rats compared to mock challenge (non-infected).
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Bp infection causes pulmonary distress.
Infection with Bp leads to mucus production, lung damage, and invasion of cellular
infiltrates into the bronchioles of the lung (35). The lungs of infants with Bp exhibit edema,
necrotizing bronchiolitis, and inflammation in the lung leading to respiratory distress (35).
WBP was used to quantify the pulmonary distress over the course of infection. Pulmonary
distress was measured by calculating the enhanced pause (PenH) of the animal (Fig. 7).
The higher the PenH value, the increased respiratory distress of the animal. PenH
corresponds with the resistance associated with peak inspiratory height (PIF) and peak
expiratory height (PEF) and taking into account time between early and late expiration
per breath (Fig. S2). With increased constriction, the expiratory peak becomes prominent
and the area of the (PEF) becomes a larger percentage of the complete expiratory area.
Others factors that contribute to the increased PenH is a decrease in relaxation time (Tr)
in relation to expiratory time (Te). Previous research has shown that severe inflammation
in the lung of mice directly correlated with an increase in PenH (36). More recently, SARSCoV-2 infected mice were observed to have subtle but significant increase in PenH post
challenge (37, 38). Compared to the mock challenged rats both D420 and Tohama 1
infected rats had an increase in PenH (Fig. 7). We observed a significant increase at day
9 with rats infected with D420 and at day 6 with rats infected with Tohama 1 compared to
mock challenge.

Histological assessment of the lung and nasal cavity
To further evaluate the inflammation in the lung, we utilized histology to confirm both
acute and chronic inflammation in response to Bp infection. At days 1, 3, 6, 9, and 12 post
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challenge the left lobes were collected, sectioned, and stained with hematoxylin and eosin
(H&E) (Fig. 8A&C). Whole-lung images were taken to assess cellular infiltration (Fig. S3).
Once stained, the blinded slides were then scored by a board-certified pathologist. Mock
challenge animals exhibited minimal inflammatory infiltrates consisting of focal
accumulations of mononuclear cells in the parenchyma and occasional infiltrates of
neutrophils surrounding blood vessels (Fig. 8A). Rats infected with Tohama 1 and D420
had significant increase in their acute inflammation scores compared to mock challenge
animals at day 1 and 3 post infection (Fig. 8B). Day 1 post infection had the highest acute
inflammation score (Fig. 8B). Rats exhibited mild to moderate neutrophil infiltration of the
parenchyma, blood vessels, and the bronchioles (Fig. 8A).

Markers of acute

inflammation resolved after day 6 post challenge; however, infected rats at day 9
exhibited obvious differences in the lung associated with mild to moderate infiltration of
mononuclear cells and higher chronic inflammation compared to mock challenge animals
(Fig. 8C). At day 12 post infection, we notice moderate resolution of inflammation in both
D420 and Tohama 1 infected rats (Fig. 8B&D). We also observed a significant increase
in lung weight, which can also be associated with elevated inflammation, at days 1 and 9
post challenge in D420 infected rats compared to the mock challenge control (Fig. 9A).
At day 12 post challenge rats infected with Tohama 1 had a significant increase in lung
weight compared to the mock challenge rats (Fig. 9A). These results confirm that Bp
infection induces inflammation in the lung of coughing Sprague-Dawley rats.

Due to the fact that Bp is a mucosal pathogen, we sought out to investigate any
phenotypic changes or inflammation in the Nasal-Associated Lymphoid Tissue (NALT) of
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pertussis infected rats via histology. NALT helps elicit immunity against airborne and
mucosal pathogens (39). The NALT is located above the hard palate and studies have
also shown that with the introduction of antigen via vaccination or bacterial components,
cellular expansion of the NALT ensues (40–44). The NALT was stained with H&E, and
we observed an increase in cellular infiltrate and a size enlargement in the NALTs of Bp
infected rats compared to the mock challenged (Fig. 10A). ImageJ analysis was used to
measure the area of both the left and right NALT of each animal (Fig. 10B). This data
could mark the potential cellular expansion of the NALT upon infection with Bp. Further
analysis of the expanding cell populations in the NALT will warrant more analysis
especially in the context of vaccine immunity.
D420 infected rats have increased bacterial burden in the respiratory tract.
We determined bacterial burden in the respiratory tract for Tohama I and D420 challenged
rats at days 1, 3, 6, 9, and 12. Over the coughing timeline, we see an overall decrease
in viable bacteria in the lung, trachea, and nasal cavity. In the lung, we observed a
significant increase in the recovered bacteria in the D420 infected rats compared to the
Tohama 1 infected rats at both days 1 and 3 (Fig. 11A). The same trend is also seen in
the nasal cavity at day 1 post infection (Fig. 11C). We observed no difference in the viable
bacteria recovered in the trachea (Fig. 11B). Previous pertussis studies utilizing the rat
model of pertussis noted weight loss from intrabronchial infection of Bp strain 18-323 (10).
Bp infection is sufficient to cause weight loss in rats (10). To confirm this using intranasal
infection, body weight was measured before challenge and upon euthanasia to calculate
percent weight change. We observed a significant decrease in weight gain in rats infected
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with Bp strain D420 and Tohama 1 compared to the mock challenged at day 12 post
infection (Fig. 9B-D).

Next, we aimed to compare the bacterial colonization between outbred mice and rats in
an effort to relatively compare the bacterial burden between models. We utilized the
bacterial burden data in CD1 mice and compared them to our data in rats (45). To
address the body weight differences between the mice and rats, we used the CFUs/organ
and divided them by their respective body weight for a crude comparison. Our data
suggests that despite having a higher initial challenge dose in the rat, the bacterial burden
remaining in the respiratory tract is higher in a mouse compared to the rat later during
infection (Fig. S4). In general, the rat model is likely a lower challenge dose per body
weight model of pertussis compared to mouse models.
Immunofluorescence confirms colonization of Bp in the lungs and nasal cavity.
We next wanted to assess the location of bacterial colonization in the nasal cavity and
visualize any bacteria left behind following flushing of the nares. We sectioned the skulls
after flushing the nasal cavity and utilized Immunofluorescence (IF). After visually
scanning the nasal cavity with confocal microscopy, we found bacteria in the nasal
turbinates and the NALT (Fig. 12A&C). We also confirmed that the bacteria were found
between the epithelial cells (Fig. 12B). The relative locations of where the bacteria were
found in the nasal cavity can be seen in (Fig. S5A). Our results show that Bp remained
in the nasal cavity over the entire course of infection even after flushing the nares (Fig.
S5B). The flushing of the nasal cavity underrepresents the total number of Bp in the nasal
cavity. In the lung, Bp colonizes the bronchioles, while the alveolar spaces remain non63

colonized (Fig. 12D&F). IF was performed on the nasal cavity and lung of mock challenge
animals to access non-specific binding (Fig. S6). To assess any potential differences
between the strains we blindly manually counted the labeled microcolonies in the lung
and nasal cavity. It is also worthy to note, we found no differences in microcolony counts
in the lung or nasal cavity between the strains (Fig. S5 C-D) despite our observed
differences in bacterial burden by CFU enumeration. CFU is likely a better indicator of
overall bacterial burden, but IF revealed that some Bp remains in the airway following
flushing of the nares.
Measurement of recruitment of neutrophils in response to Bp infection
Previous studies utilizing the rat model of pertussis noted leukocytosis and an increase
in the amount of total white blood cells using agar-encased Bp for infection (8).
Neutrophils circulating through the blood were measured during intranasal infection by
antibody staining and flow cytometry, as Bp infection results in varying amounts of
neutrophilia (35, 46). One caveat of analyzing cell populations via flow cytometry in the
rats is the limited availability of rat specific antibodies compared to mice. Recent research
by Barnett-Vanes et al has developed a flow cytometry panel to analyze cell populations
in a model of LPS-induced pulmonary inflammation (47). The percentage of CD45+
(CD161- B220- CD43+ His48Hi) neutrophils in the blood were assessed in Bp infected
rats compared to the mock challenged animals (Fig. 13A). Specifically, a significant
increase in the number of circulating neutrophils in the blood of rats infected with D420 at
days 1 and 9, with Tohama 1 infected rats only having a significant increase to mock
challenge at day 9 (Fig. 13A). Next, cytokines concentrations in the lung and serum were
measured to identify factors that could contribute to the recruitment of neutrophils,
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specifically IL-6 and IL-17. IL-6 is a potent inducer of Th17 polarization and been found
elevated during murine infection with Bp (45, 48–50). Surprisingly, we did not observe
any significant changes in IL-6 due to Bp infection (Fig. 13B&C). It has been well
documented in the mouse model that the production of IL-17 in pertussis plays a role in
the increase of circulating neutrophils (51). There were no significant changes in IL-17a
in the serum or lungs of Bp infected rats compared to mock challenge (Fig. 13D&E). Th1
and Th2 cytokines and chemokines in the lung and serum were also measured (Fig. S7Fig. S10). We did not observe an increase in the induction of cytokines by infection
overall; however, in the serum, rats infected with D420 had a significant increase in IL-5
compared to Tohama 1 infected rats at day 12 post infection (Fig. S7). There was a
significant increase in IL-5 and TNF-alpha at day 6 post infection in the lung in rats
infected with Tohama 1 compared to D420 (Fig. S8). We also observed significant
increases in chemokines MIP-1a, RANTES, MCP-3, MIP-2, and IP10 in rats infected with
D420 at day 12 post challenge in the serum compared to rats infected with Tohama 1
(Fig. S19). In the lung, MIP-2 and IP10 were increased in rats infected with D420
compared to mock challenge control (Fig. S10). Despite slight differences highlighted
above we did not observe a massive difference in the cytokine and chemokine responses
during infection.
Serological analysis of Bp specific antibodies
Enzyme-linked immunosorbent assays (ELISA) were performed to determine the
serological response generated from Bp infection. We measured IgM and IgG antibody
titers in the serum to whole bacterium and Bp associated virulence factors at days 1, 3,
6, 9, and 12 post infection. In previous studies utilizing the rat model, intrabronchial
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infection induced the generation of IgG antibody titers to sonicated Bp 28 days post
infection (8). Intranasal infection of strain D420 has generated significant anti-PT IgG
antibody titers in the baboon model at days 17-19 of infection (26). However, analysis of
antibody titers generated against an intranasal pertussis infection in the rat has yet to be
determined and we wanted to characterize the primary antibody response to Bp (Fig.
S11). We observed a significant 10-fold increase in the anti-Bp IgM antibody response at
day 9 and an almost 20-fold increase 12 days post challenge in rats infected with D420
compared to mock challenge, while we also saw a significant 6-fold increase in anti-Bp
IgM at day 12 post infection to the amount of anti-Bp IgM from Tohama 1 infection (Fig.
14A). At day 12 post infection, we observed that Bp infection induced significant
production of anti-Bp IgG in the serum compared to mock challenge animals (Fig. 14F).
At day 12 post infection, Tohama 1 infected rats had a significant increase, nearly double
anti-Bp IgG antibody titers compared to rats infected with D420. AUC analysis revealed
a significant increase in anti-Bp IgM antibodies from rats infected with D420 compared to
Tohama 1 infected rats (Fig. S12A). However, no difference was observed in AUC of the
anti-Bp IgG antibody response over the total course of infection between the bacterial
challenge groups (Fig. S12B). It is also important to note we also did not see a significant
increase in the generation of antibodies titers to PT, ACT, PRN, and FHA in Bp infected
rats compared to mock challenge infected animals (Fig. 14B-E, G-J). We would also like
to note that IgA antibodies were not detected to either whole bacteria or PT in the lung
and nasal cavity at days 1 and 9 post challenge (data not shown).
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2.4 Discussion
To date, the only known reservoir for Bp is humans, making the development of a suitable
animal model challenging. Multiple models have been studied to recapitulate similar
disease symptoms seen in humans, as well as provide insight into the pathogenesis of
Bp. We set out to re-investigate the rat model of pertussis that was originally introduced
in 1938 (6). In our study, we have confirmed that intranasal administration of Bp led to
bacterial colonization of the upper and lower respiratory tract (Fig. 11). Through intranasal
instillation, bacteria were able to infect the nasal cavity, trachea, and lung post challenge.
This is important to note as infants with pertussis experience pneumonia more frequently
than adolescents and adults (35). Mouse models of pertussis also rely on depositing
large numbers of bacteria into the lung to establish infection (2). Here, our data shows
that through intranasal infection, we establish an infection of both the upper and lower
respiratory tract, resembling the infection seen in adolescents and adults with pertussis
(52, 53).
Previous reports have shown Bp infection of rats induced paroxysmal coughs, and these
coughs were counted by analog audio recordings (7). Utilizing WBP we are able to
precisely and digitally count coughs and measure respiratory capacity for the first time
with rats infected with Bp (Fig. 6&7). Here, coughs induced from infection appeared at
day 1-2 post challenge, with the number of coughs gradually increasing with peak cough
occurring at day 8 post challenge. Rats challenged with intrabronchial instillation of Bp
noted similar peak cough counts approximately 10 days post challenge (54). This is also
one of the first studies utilizing WBP to count coughs in rats with bacterial infection. We
did observe some infected rats that did not overtly cough. This reflects the frequency of
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coughs in adolescents and adults (55). Previous studies using baboons also show that
Bp infection elicits severe coughs lasting over 2 weeks post challenge with peak coughs
per hour being at day 4 post challenge (26). It is also important to note that at peak
coughing, the bacterial burden was low, which was also observed in previous Bp infected
rat research (7). The data suggest that other factors could be playing a role in cough
production despite the bacterial infection being resolved. Given that Bp infected rats
coughed, we also investigated transmission of Bp from infected 7-week-old rats (actively
coughing) cohoused with more susceptible 3-week-old rats and we have observed no
evidence of transmission via negative qPCR (IS481) analysis of swabs from the nasal
cavity and no active coughing in the naïve 3-week-old rats. We also performed a
challenge study with Bb strain KM22 in 7-week-old Sprague Dawley rats, and challenged
rats coughed violently and earlier after bacterial challenge compared to Bp infected rats.
Bb infected rats coughed the most when the bacterial loads in the respiratory tract were
at their highest, which could potentially lead to transmission of the bacterium. TLR4
deficient rats could be investigated to evaluate transmission of Bp (56). We have also
observed that the increased bronchi restriction coincides with the increased coughs
during days 6-11 post challenge (Fig. 7). The decreased lung capacity and increase in
cough could be further associated with an increase of chronic inflammation in the lung
(Fig. 8). Our data suggests that the coughing rat model of pertussis can be used to
potentially evaluate the mechanism of cough, which still requires further investigation.

Initial studies characterizing the serum antibody response to rats infected with Bp noted
an increase antibody response to endotoxin correlated with the low amount of cultivable
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organisms in the lung following intrabronchial challenge (7). Hall et al. demonstrated that
rats infected with Bp become sera positive to whole cell Bp lysate, FHA, and PT at 28
days post intrabronchial challenge (8). Anti-FHA antibody titers were not detected until
day 16 post challenge, while anti-PT antibody titers were not detected until day 28 post
challenge (23). In our study, we characterized the antibody response following intranasal
challenge of Bp over the whole infection timeline. Using Bp coated ELISA plates, we
detected anti-Bp IgG antibody titers in rats infected with Bp at day 9 post challenge with
a significant increase compared to mock challenge observed at day 12 (Fig. 14). We also
measured a significant increase in anti-Bp IgM antibody titers in rats infected with D420
compared to the mock challenge and Tohama 1 infected animals (Fig. 14). One potential
hypothesis that could explain this observation is the genetic differences between the two
strains as D420 harbors the ptxP3 allele, leading to an increase in PT production (25).
PT has been shown to suppress Bp antibody responses in the serum and limit expression
of antigen presenting receptors (57–60).
With the increased interest in developing new pertussis vaccines, it is imperative for the
development of animal models to evaluate the pathogenic potential of current emerging
strains, as well as identify any potential differences in disease burden between genetically
divergent strains. Sato and Sato first used Bp strain Tohama 1 in the development of the
acellular pertussis vaccine, and Tohama 1 is still being used in pertussis research today,
notably due to its genetic malleability (61). D420 has been instrumental in the
development of the baboon model and has also been used to study vaccine efficacy in
regards to transmission in the baboon model (29). We hypothesize that the observed
differences could be due to the increased amount of PT through the ptxP3 allele of D420
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(25). Strains, such as D420, harboring the ptxP3 allele lead to increase in virulence, PT
production, and prevalence (62, 63). A previous study utilizing the intranasal mouse
model has shown an increase in bacterial colonization with ptxP3 strains (64). Parton et
al. illustrated that infection with a PT deficient strain was unable to induce cough (9). It is
possible that there are other factors beyond PT that can account for the observed
virulence differences between Tohama I and D420. In the rat model, unlike the mouse,
we also did not measure any significant increases in IL-17 and IL-6 in the lung and serum
following challenge. IL-17 and IL-6 are increased following Bp infection in mice and
baboon (30, 48, 65). Further investigation is needed to explain the observed differences.
One potential approach to evaluate differences between strains is the use of a neonatal
rat model of pertussis. Studying Bp in neonates may be useful in distinguishing subtle
differences between strains. Hornibrook et al demonstrated that Bp infected young 3
week rats had 65% mortality, while 7 week old rats do not succumb to infection with similar
dose (6).

In summary, we have demonstrated that the rat model of pertussis can be used as a tool
to further study Bp pathogenesis and recapitulate some of the similar symptoms of
pertussis as seen in humans. Pertussis is often described as a 100 day cough, because
adolescents and adults extended duration of coughing (66). Coughing episodes in infants
with pertussis can lead to vomiting, choking, gagging, and apneic episodes that can lead
to seizures (67). Mice have not been used to evaluate coughing manifestation in pertussis
until recently, and baboons are expensive and limited to specialized facilities (68). The
coughing rat of pertussis provides feasibility through low husbandry costs, availability of
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animals, and ease of use as a model. The immunological tools available in murine
research is vast but as basic research continue to evolve, so will the resources and
immunological tools available for rats. Recently flow cytometry markers have been
developed to study innate immune cells, and adaptive immune cells such as B and T cells
(47). In other studies, we have ELISpots assays to investigate antigen specific immune
populations as well. Increasing availability of antibodies has also allowed for investigating
systemic and mucosal serological responses. Future studies utilizing the coughing rat
model of pertussis will capitalize on the growing immunological toolbox in regard to
vaccination against pertussis.

In this study, we carefully compared two established strains that have been used in the
pertussis field, Tohama 1 and D420. In future studies, we aim to evaluate whole cell and
acellular vaccine mediated immunity against D420. Armed with this model, we can further
our understanding of pathogenesis, host response during pertussis, genetic divergence
between strains, and vaccine-mediated immunity.
2.5 Materials and methods
Bordetella pertussis strains and growth conditions. Bp strain Tohama 1 was
graciously provided by Dr. Peter Sebo (Czech Academy of Sciences) and strain D420
was acquired from the CDC Pertussis Lab provided by Drs. Maria L. Tondella and Michael
Weigand. Bp strain Tohama 1 and D420 were cultured on Bordet Gengou (BG) agar
(RemelTM Cat. R45232) that was supplemented with 15% defibrinated sheep blood
(Hemostat Laboratories Cat. DSB500) (69). Bacteria were cultured on BG plates for 48
hrs at 36°C. Bp was transferred from BG plates with polyester swabs (Puritan Cat. 22-
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029-574) and transferred into 20 ml Stainer-Scholte liquid media (SSM) in new 125 ml
flasks (Thermo Fisher Scientific Cat. FB500125) (70). The liquid cultures were grown for
24 hrs at 36°C inside a shaking incubator at 180 rpm.

Intranasal challenge with B. pertussis. Seven-week-old ~170g female SpragueDawley rats (Charles River Cat. 001CD) were used for challenge. Bp was grown as
described above. The rats were then anesthetized with ketamine and xylazine 50-100/510 mg/kg and challenged with 108 CFUs (100µl intranasally), administering two 50µl
doses one in each nostril (Fig. 5). Body weight of each rat was recorded before challenge
and immediately post euthanasia. Rats were euthanized at day 1, 3, 6, 9, and 12 post
bacterial challenge. Mock challenge animals (no bacteria) were administered 100µl of
sterile endotoxin free phosphate buffer saline (PBS) (Thermo Fisher Scientific Cat.
TMS012A) intranasally. Upon euthanasia blood was collected via cardiac puncture and
transferred into ethylenediaminetetraacetic acid (EDTA) (BD Cat. 365974) and serum
separation (BD Cat. 026897) tubes. Blood collected in the EDTA tube was used for flow
cytometric analysis, while blood collected in the serum separation tubes were used to
isolate the serum via centrifugation (15,000 x g for 3 min) and used for serological and
cytokine analysis. Lung and trachea were excised and homogenized to determine
bacterial burden. Upon removal, the wet weight of the lungs was recorded. Lungs were
then collected in gentleMACS C tubes (Miltenyi Biotec) and homogenized using
gentleMACS™ Dissociator (Cat. 130-095-927). The trachea was homogenized using a
Polytron homogenizer. To determine the bacterial burden in the nares, 2mls of sterile 1x
PBS was flushed through the nares and collected for plating. Serial dilutions of the
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homogenates and nasal collection were plated on BG plates supplemented with
ceftibuten (Sigma-Aldrich Cat. SML0037) 10 µg/ml to decrease growth of normal rat
respiratory tract flora.

Analysis

of

coughing

and

bronchiole

restriction

using

whole-body

plethysmography. To quantify respiratory function during infection, we utilized a Buxco®
FinePointeTM Whole Body Plethysmograph instrument (WBP) (DSI). FinePointeTM
software was used for collecting, analyzing, and reporting the breathing data. Everyday
post challenge for twelve consecutive days at 5:00PM the rats were placed inside
designated chambers to acclimate for 5 min. We chose this time, not only due to rats
being nocturnal, but this was the time the animals were most awake and active as
confirmed by video camera (data not shown). Following acclimation, the rat’s respiratory
profile was recorded for 15 min. Each chamber is fitted with a transducer that measures
the changes in box flow and airflow of the subject. The chambers are also fitted with a
screen pneumotach that allows airflow in and out of the chamber that can be recorded.
Coughs were counted during the designated 15 min, and enhanced pause (PenH) was
calculated to signify bronchiole restriction. Coughs were counted based on large box flow
changes of the subject, and changes in both humidity and temperature of the air flowing
in and out of the subject with classical cough-like waveforms. Cough detection algorithm
is applied with patented fuzzy logic criteria to determine if the event is a cough (71). When
analyzing the number of coughs, each cough in a multi-cough event was counted
individually.
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Histological assessment of the lung and nasal-associated lymphoid tissue. Upon
euthanasia, the rat skull was excised, and the mandible removed. The skulls were fixed
in 10% formalin (Fisher Scientific Cat. SF98-4) for 48 hrs at 26 °C. After fixation, formalin
was removed, and skulls were frozen at -80 °C until decalcification. Skulls were decalcified with Richard-Allan Scientific decalcifying solution (Thermo Scientific Ref. 83401) at room temperature for 24-48 hrs and embedded in paraffin. Samples were sectioned
and stained with Hematoxylin-Eosin (H&E). A Biotek Lionheart Fx was used to scan and
image the NALT. ImageJ was used to trace and measure the area of both the left and
right NALT using the images from the Lionheart Fx. The left lobe of the lung was excised
and fixed in 10% formalin 48 hrs at 26 °C. The left lobe was then embedded in paraffin
and stained with H&E by the WVU Pathology Department. H&E stained sections were
used to characterize and score acute and chronic inflammation of the lung. All scorings
were done by a board-certified pathologist (iHisto). Individual scores were based on a
standard qualitative scoring criterion: (0 – none, 1 – minimal (rare), 2 – mild (slight), 3 –
moderate, 4 – marked, 5 –severe). Chronic inflammation was characterized by
mononuclear infiltrates of the parenchyma, blood vessels, and airway. Acute inflammation
scores were assigned due to the presence of neutrophils in the parenchyma, blood
vessels, and airway. All examination and scoring were performed blindly as no knowledge
of treatment groups were known.

Imaging of Bp in the lung and nasal cavity. Detection of Bp in the nasal cavity and the
lung were quantified via immunofluorescence (IF) and confocal imaging. The left lobe of
the lung and nasal cavity were preserved and sectioned as described above. Sectioned
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samples underwent deparaffination and rehydration using xylene and ethanol (100%70%). Antigen retrieval was performed by incubating samples in citrate buffer at 98 °C for
20 min. Samples were blocked using 5% Bovine Serum Albumin (BSA) (Fisher Scientific
Cat. 159008) for 1 hr and primarily labeled utilizing a polyclonal rabbit FHA antibody (Gift
from Dr. Erik Hewlett) diluted in 1x PBS. Secondary labeling occurred utilizing an antirabbit IgG conjugated with Texas Red (Fisher Scientific Cat. T2767) diluted in 1x PBS.
Samples were then covered in mounting media (Prolong Gold Antifade reagent with DAPI
Cat. 8961). Samples were imaged using a Nikon A1R confocal microscope. Images were
analyzed on DAPI channel and at wavelength 650nm for Texas-Red acquisition. Images
were acquired using 100x oil immersion lens (100x/1.40 Nikon Plan APO). To identify any
potential differences in IF between the two strains, all IF images were deidentified and
the microcolonies were manually counted blindly by four volunteers with 2-3 fields of view
used per sample.
Flow cytometry analysis of phagocytes. Neutrophil recruitment in the blood was
evaluated by flow cytometry. Blood samples upon collection were then lysed with
Pharmylse buffer (BD Biosciences Cat. 555899) for 20 min at room temperature, with
slight vortexing throughout. The remaining cells were resuspended in RPMI + 10% FBS
to neutralize the lysis buffer, then centrifuged at 1,000g x 5 and washed with the RPMI
+10% FBS again. Blood was then resuspended in 1%FBS+PBS+5mM EDTA. Samples
were then block with anti-CD32 (BD Pharmingen Cat. 550270) antibody for 30 min at 4°C.
After incubation, the cells were stained with the appropriate antibody markers; CD45
Alexa flour 700 (Biolegend Cat. 202218), CD161 APC (Biolegend Cat. 205606), CD45R
PE Cy7 (eBioscience Cat. 25-0460-82), His48 FITC (eBioscience Cat. 11-0570-82),
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CD43 PE (Biolegend Cat. 202812), and CD3 VioGreen (Miltenyi Biotec Cat. 130-119125) (47). After the addition of antibodies, the cells incubated 1 hr at 4°C in the dark. To
prepare the lung samples for flow cytometry, the lung homogenate was pushed through
a 70 µm cell strainer (BioDesign Cell MicroSives Cat. N70R), creating a single-cell
suspension. The suspension was centrifuged at 1,000 x g for 5 min. After removal of the
supernatant, the pellet was resuspended in Pharmlyse buffer and the cells incubated at
37°C for 2 min. After incubation, the cells were centrifuged at 1,000 x g for 5 min,
supernatant was removed and blocked and labeled with antibody as described above.
The lung and blood samples were centrifuged at 1,000 x g for 5 min and the pellets were
resuspended in 0.4% paraformaldehyde and stored overnight at 4°C. Samples were
washed with 1x PBS and resuspended in 1x PBS for analysis. Cell samples were
analyzed on a LSR Fortessa and samples were gated and analyzed using FlowJo v10.
Lung and serum cytokine and chemokine analysis. Lung homogenate samples were
centrifuged at 19,000× g for 4 min and the supernatant was removed and stored at
−80 °C. Quantitative analysis of cytokines in the serum and lung homogenate was
performed using ProcartaPlex Multiplex Immunoassay kit: Cytokine & Chemokine 22Plex Rat ProcartaPlexTM Panel (Cat. EPX220-30122-901) per the manufacturer’s
instructions.

Serological analysis. Antibody titers of infected rats were measured by ELISA.
Bordetella pertussis specific ELISA plates were coated with 50 µl of 108 B. pertussis
grown as mentioned above for infection. For measurement of antibody titers to FHA (Enzo
ALX-630-123-0100), PRN (GSK), PT (List Biological Laboratories #180), and ACT (Gift
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from Dr. Erik Hewlett), we coated plates with 50 µl of each antigen at 1µg/ml. Once
coated, plates incubated over night at 4°C. Plates were washed with 1x PBS-Tween 20
and blocked with 5% skim milk for 2 hours at 37°C. Plates were washed again and the
serum from the challenge studies were serially diluted down the ELISA plate and
incubated for 2 hours at 37°C. After incubation, the plates were washed and coated with
100µl of secondary goat anti-rat IgG (SouternBiotech Cat. 3030-04) and IgM
(SouhternBiotech Cat. 3020-04) antibody at a dilution of 1:2,000 in PBS + 5% milk. Once
coated, the plate was incubated for 1 hour at 37°C. Plates were then washed again with
PBS-Tween 20 and 100 µl p-nitrophenyl phosphate substate (Thermo Scientific Cat.
37620) was added, prepared by manufactures instructions, and the plate was developed
for 30 min at room temperature for titers to IgG and IgM. Biotek Synergy H1 microplate
reader was used to measure the colorimetric signal of the ELISA plate at A450. Positive
antibody titers were determined by any values that were higher than the baseline. The
baseline is set as double the average value of the blank, no serum added to these wells.
Generating Nightingale rose plots in Python: Data from individual mice were averaged in
Microsoft Excel and log transformed. Values were formatted in Excel to be compatible
with Python. Data were imported from .csv files using the pandas package and plotted
using the “Barpolar” representation feature in the plotly.graph_objects module. Samples
with a titer less than 50 were assigned a value of 0.

Statistical analysis. All data was analyzed using GraphPad Prism 7. The minimum
biological replicates for the challenge studies were four. For statistical comparisons
between multiple groups over the entire course of the infection a two-way analysis of
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variance (ANOVA) was used One-way ANOVA was used for comparison between groups
for each individual day with Tukey’s post hoc test. Unpaired Student t-tests were used for
area under the curve (AUC) analysis. Follow-up statistical tests are annotated in figure
legends.

Data availability. Data requests for figures provided can be addressed to the
corresponding author.

Ethics statement. All studies were performed in accordance West Virginia University
Institutional Animal Care and Use Committee approved protocol 1811019148.6.
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Figure 5. Experimental design of intranasal infection of Bp. Schematic representation of
Sprague-Dawley rats intranasally infected with Bp. Whole body plethysmography was
used to measure cough and analyze lung function over the course of a twelve-day
infection. Body weight, Bacterial burden of the respiratory tract, innate lymphoid
recruitment, and antibody titers were measured at the days 1, 3, 6, 9, and 12 post
challenge. The left lobe of the lung and NALT were sectioned and stained with
hematoxylin and eosin for histological analysis and immunohistochemistry was performed
to visualize bacteria in the left lobe of the lung and nasal cavity.
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Figure 6. Infection of Bordetella pertussis induces cough in Sprague-Dawley rats.
Coughs were measured each day of the twelve-day infection using whole body
plethysmography. Coughs were counted for (A) mock challenge rats, (B) rats infected
with D420, and (C) rats infected with Tohama 1. (D) Summary of results (A-C) shown as
mean ± SEM (n = 4-8). (E) Area under the curve is represented as averages of coughs
per fifteen minutes for each rat. P values were determined by two-way ANOVA followed
by a Bonferroni comparison test and unpaired Student t-test for AUC, *P < 0.05 D420
compared to the mock challenged control group, #P < 0.05 Tohama 1 compared to the
mock challenged control group.
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Figure 7. Bordetella pertussis infection impairs respiratory capacity. Over the course of
infection, Sprague-Dawley rat's respiratory function was analyzed using whole body
plethysmography. Each day at 5p.m., rat’s bronchial restriction was determined by
utilizing WBP by calculating for PenH. Results shown as mean ± SEM (n = 4-8). P values
were determined by two-way ANOVA, *P < 0.05, **P < 0.01 compared to the mock
challenge group followed by Dunnett’s comparison test.
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Figure 8. Bp infection induces acute and chronic inflammation in the lung of SpragueDawley rats. The left lobe of the lung was sectioned and stained with hematoxylin and
eosin from rats infected with D420, Tohama 1, or the PBS control. (A) Representative
images of acute inflammation demonstrating neutrophil recruitment around surrounding
blood vessel (asterisk) and parenchyma (arrows) at 400x magnification. (B) Average
acute inflammatory score of the lung by the predominance of neutrophils in the
parenchyma, blood vessels, and airways. (C) Representative images of chronic
inflammation showing mononuclear cells surrounding the blood vessel (asterisk), lamina
propria (arrow), and bronchioles (arrowhead) at 200x magnification. (D) Average chronic
inflammatory score of the lung characterized by mononuclear infiltrates in the
parenchyma, blood vessels, and airway. Histological assessment was determined
blinded with no knowledge of the treatment groups. Results are shown as mean ± SEM
(n = 4) P values were determined by one-way ANOVA followed by Dunnett’s comparison
test, *P < 0.05 compared between challenge groups. #P < 0.05, ##P < 0.01 compared to
mock challenge.
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Figure 9. Bp infection induces inflammation of the lung and decrease in weight gain. (A)
Post euthanasia, the lung weight was measured and recorded. To observe any weight
changes over the course of infection, we calculated percent weight change for (B) mock
challenge, (C) D420, (D) Tohama 1 infected rats. Rats body weights were recorded before
infection as well as immediately post euthanasia. Percent weight change was calculated
by taking the differences between starting weight and end weight and dividing by the initial
weight and multiplying by 100. Results shown as mean ± SEM (n = 1-4). Only one mock
challenge rat weight was measured at days 1, 3, 6, and 9. P values were determined by
one-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001, compared to the mock challenge group.
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Figure 10. Analysis of the nasal associated lymphoid tissue. The skull was sectioned
allowing for staining of the NALT with hematoxylin and eosin. (A) Representative 20x
images of the NALT. Arrows indicate the NALT. (B) ImageJ analysis analysis of the area
of both the left and right NALT. Dotted line represents the average area of the NALT in
the mock challenged group. Results shown as mean ± SEM (n = 4). P values were
determined by two-way ANOVA, *P < 0.05, ***P < 0.001, ****P < 0.0001 compared to the
mock challenge group.
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Figure 11. Analysis of bacterial burden over the course of Bp infection. Bacteria were
quantified by serially diluted CFUs following intranasal challenge. CFU counts were
determined from (A) lung homogenate (B) trachea and (C) nasal lavage. Results are
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Figure 14. Measurement of serum antibody titers over the course of B. pertussis infection.
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2.8 Supplemental Figures

Laminar flow hood

Monitoring screen

WBP

Rat chamber

Figure S 1. Set up for the whole-body plethysmograph (WBP). Pictured far left on the
table is the WBP and computer. Pictured on the right in the bio safety hood are the
chambers where the rats are monitored.
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Figure S 2. Diagram illustrating Penh during Bp infection. Enhanced pause (Penh) is a
calculation that is used as a measurement for respiratory distress. Peak expiratory height
(PEF) constitutes as the maximum expiratory flow that occurs in one breath; peak
inspiratory flow (PIF) is the maximum inspiratory flow that occurs in one breath;
Inspiratory time (Ti) the time it takes from the start to end of the inspiration phase of the
breath; expiratory time (Te) the amount of time it takes from the start for the expiration to
the end of the respiration; relaxation time (Tr) the time it takes the subject to expel certain
amount of volume. Following Bp challenge, infected rats have an increase in respiratory
distress compared to mock challenge rats.
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Figure S 3. Bordetella pertussis infection induces cellular recruitment in the lungs. (A)
The left lobe of the lung was sectioned and stained with hematoxylin and eosin of rats
infected with D420, Tohama 1, or the PBS control. Representative pictures shown are
multiple 4x magnification images stitched together for each lung.
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rats. To assess the effect of body weight on bacterial colonization, we took CFUs for each
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came from (Boehm 2018). Results are shown as mean ± SEM (n = 4) P values were
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Figure S 7. Serum cytokine response during twelve-day Bordetella pertussis infection.
Cytokines measured include: (A) IL-2, (B) IL-4, (C) IL-5, (D) IL-10 (E) IL-13, (F) TNF-𝛂,
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Results shown as mean ± SEM (n = 4). P values were

determined by one-way ANOVA followed by Tukey comparison test, #P < 0.05 compared
between infection groups.
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Figure S 9. Serum chemokine during twelve-day Bordetella pertussis infection.
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Figure S 10. Lung chemokine during twelve-day Bordetella pertussis infection.
Chemokines measured include: (A) MCP-1, (B) MIP-1a, (C) RANTES, (D) MCP-3, (E)
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concentration of the mock challenge control group. Results shown as mean ± SEM
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test. *P < 0.05, ***P < 0.001 compared to mock challenge.
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infection. ELISA was used to compare serological responses from rats IN challenge with
B. pertussis. Total IgM (A-B) and IgG (C-D) serum antibody titers were measured from
challenged rats against Bp, FHA, PRN, PT, and ACT. (n = 4). P values were determined
by two-way ANOVA corrected with Bonferroni comparison test, *P < 0.05, ***P < 0.001,
****P < 0.0001 compared between infection groups. For comparison to mock challenged
control group one-way ANOVA was used followed by Tukey comparison test, #P < 0.05,
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3.1 ABSTRACT
Pertussis is a respiratory disease caused by the Gram-negative pathogen, Bordetella
pertussis (Bp). The transition from a whole cell pertussis vaccine (wP; DTP) to an
acellular pertussis vaccine (aP; DTaP; Tdap) correlates with an increase in pertussis
cases, despite widespread vaccine implementation and coverage, and it is now
appreciated that the protection provided by aP rapidly wanes. To recapitulate the
localized immunity observed from natural infection, mucosal vaccination with aP was
explored using the coughing rat model of pertussis. Immunity induced by both oral gavage
(OG) and intranasal (IN) vaccination of aP in Bp challenged rats over a nine-day infection
was compared to intramuscular (IM)-wP and IM-aP immunized rats that were used as
positive controls as IM immunization is the current route for wP and aP vaccination. Our
data demonstrate that both IN and OG immunization of aP resulted in production of antiBp IgG antibody titers similar to IM-wP and IM-aP vaccinated controls post-challenge. INaP also induced anti-Bp IgA antibodies in the nasal cavity. Immunization with IM-wP, IMaP, IN-aP, and OG-aP immunization protected against Bp induced cough, while OG-aP
immunization did not protect against respiratory distress. Mucosal immunization (IN-aP
and OG-aP) also protected against acute inflammation and decreased bacterial burden
in the lung compared to mock vaccinated challenge (MVC) rats. The data presented in
this study suggests that mucosal vaccination with aP can induce a mucosal immune
response and provide protection against Bp challenge.
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3.2 Introduction
Infection of the respiratory mucosa by the Gram-negative bacterium Bordetella pertussis
(Bp) causes the disease known as pertussis (whooping cough) (1). Clinical manifestations
of pertussis are characterized by paroxysmal cough, hypertension, leukocytosis and in
severe cases death, particularly in infants who have yet to receive their first vaccine dose
(2–4). Before pertussis vaccines were introduced in the United States, pertussis led to
approximately 200,000 deaths annually (5). Largely, this disease has been under control
by the use of diphtheria tetanus whole-cell pertussis (DTP; wP) and acellular pertussis
(DTaP; Tdap; aP) vaccines. DTP was first introduced in the 1940s/1950s, and was largely
effective in decreasing pertussis incidence (6). Due to the robust immune response and
reactogenicity concerns, developed countries converted to the use of DTaP in the 1990s
(2).

Since the introduction of the aP vaccine, pertussis cases have been increasing, despite
high vaccine coverage. It has been hypothesized that the increase in pertussis cases is
attributed to: waning immunity from DTaP and Tdap vaccination, vaccine driven evolution
of Bp strains, increased surveillance of pertussis, increased asymptomatic transmission,
and improved PCR based molecular identification of cases (7–13). Infant baboons
vaccinated with DTaP (1 human dose at 2, 4, and 6 months of age) were still colonized
after experimental Bp challenge in addition to subsequent transmission to naïve baboons
(14). In the same study, Warfel et al (2014) showed that convalescent baboons that
cleared a prior Bp infection, were not colonized following re-challenge of Bp one month
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later (14). In humans, studies suggest that convalescent immunity can confer protection
for approximately 4-20 years (15), while DTaP immunity falls short lasting on average 412 years (15). Overall, these data demonstrated that immunity induced through natural
infection can generate longer lasting protection that also elicits pathogen clearance. As
Bp is a respiratory pathogen, it can be hypothesized that generating an immune response
at the respiratory mucosa is necessary for protection against pertussis.

Infection with Bp localizes to respiratory epithelium primes the immune response against
subsequent Bp infection by recruitment of antibody producing cells and tissue resident
memory T cells (Trm) (16). Bacteria invading mucosal surfaces can induce inflammation
resulting in subsequent production of IgA antibodies (17). Patients previously infected
with Bp have developed IgA antibody titers in their nasal secretions (18). In addition, antiBp IgA antibodies from patients who have convalesced from Bp infection inhibit bacterial
attachment in vitro and increase Bp uptake and killing by human polymorphonuclear
leukocytes (19, 20). Convalescent humans also generate Bp specific IgG antibody titers
that have shown to correlate with protection (21, 22). Bp infected mice generate Bp
specific CD4+ T cells in the lung that secrete IFN-γ and IL-17 (23, 24). In mice, Bp
infection induced Trms in the lung and were associated with pathogen clearance (16).
Nonhuman primates previously infected with Bp generate both Th1 and Th17 memory
cells that are still detected two years post infection (25). To induce a similar protective
immune response that is observed during natural infection, mucosal vaccination has
recently been investigated (26–28)
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Mucosal immunization has been scarcely used as a vaccination strategy to generate a
protective immune response against pertussis in clinical and pre-clinical models. Oral
vaccination with wP induced the production of Bp specific antibody titers in both the saliva
and serum of newborns (29). In a subsequent study in 1985, oral immunization of 1012
CFUs of killed Bp led to the induction of antibody titers in the saliva and serum of
newborns (30). The frequency of pertussis was lower in orally vaccinated newborns
during the first year of life compared to newborns who were unvaccinated although, this
difference disappeared by the end of the year (30). In mice, oral administration of
attenuated bacterial vectors Salmonella typhimurium and Escherichia coli expressing Bp
antigen, filamentous hemagglutinin (FHA), results in the production of anti-FHA IgA
antibody titers in the lung (31). Intranasal immunization of a live attenuated vaccine strain
of Bp, BPZE1 was protective both in preclinical and clinical studies (32–35). Previously,
our lab has shown that IN immunization of DTaP can induce a protective immune
response in mice (27, 28). Boehm et al (2019) illustrated that IN vaccination of DTaP with
and without the addition of the adjuvant curdlan induces both anti-Bp and anti-pertussis
toxin (PT) IgG antibody titers, as well as Bp specific IgA in the lung (27). A subsequent
study performed by Wolf et al (2021) suggested that IN-aP vaccination is protective
through the induction of humoral responses 6 months after booster vaccination and
challenge (28). Mounting evidence supports that mucosal immunization can be protective
against Bp colonization, but murine studies lack the ability to evaluate one the of hallmark
symptoms of pertussis, Bp-induced coughing.
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The rat model of pertussis has been utilized to characterize Bp pathogenesis and
evaluate coughing manifestation from Bp infection (36–42). Only a few studies have been
performed investigating vaccine efficacy in the coughing rat model of pertussis. Hall et al
(1998) demonstrated that the SmithKline Beecham 3-component aP vaccine (detoxified
PT (PTd), FHA, and a 69kDa antigen, presumably pertactin (PRN)), the Connaught 5component vaccine (PTd, FHA, agglutinins 2+3 (fimbriae), and PRN), and Evans wholecell pertussis vaccine protected against cough upon intrabronchial Bp challenge (41).
Rats administered one single human dose of DTP had a lower incidence of coughing
following Bp challenge (39). We hypothesized that both oral and IN vaccination would
protect against bacterial burden upon challenge as well as protect against Bp induced
coughing in the rat model of pertussis by generating a protective immune response at the
site of infection. To test this hypothesis, we IN and OG vaccinated and challenged
Sprague-Dawley rats with 1/5th human dose of DTaP. IM-wP and IM-aP vaccinated and
Bp challenged rats were used as positive controls to compare vaccine-mediated immunity
as IM administration of DTaP is the current route of vaccine administration.

In our study, we aimed to use the rat model of pertussis to measure protection induced
from mucosal vaccination of DTaP. By utilizing the coughing rat model of pertussis,
protection against bacterial burden in the respiratory tract and prevention of Bp induced
cough after immunization was critically analyzed. We also focused on evaluating the
serological responses regarding vaccination followed by Bp challenge. Our data supports
that protection can be afforded by mucosal immunization with DTaP. IN and OG
immunization with DTaP not only induced systemic anti-Bp IgG antibodies but also
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induced mucosal anti-Bp IgA antibodies. These data suggest that oral vaccination of
DTaP can generate a humoral immune response at the respiratory mucosa in rats. IN-aP
and OG-aP was also capable of protecting against Bp-induced cough. Furthermore,
mucosal vaccination protected against bacterial burden in the respiratory tract. In
conclusion, this study highlights the benefits of using the coughing rat model of pertussis
to study mucosal vaccination with Bp vaccines.

3.3 Results
Intranasal immunization induces systemic anti-Bp IgG and anti-PT IgM and IgG
antibody titers following booster immunization.
We hypothesized that IN-aP and OG-aP immunization would induce systemic IgM and
IgG antibodies, as mucosal immunization stimulates the induction of both systemic and
mucosal antibodies (27, 28, 30). To test this hypothesis, 3-week-old Sprague Dawley rats
were IM-wP, IM-aP, IN-aP, and OG-aP immunized followed by a booster vaccine at 6
weeks of age with the same corresponding vaccine (Fig. S13). Mucosal and systemic
antibodies were measured over the course of vaccination (Fig. S13). Minimal differences
in antibody titers prior to booster vaccination was observed for all immunized groups (Fig.
15). Compared to all other groups, IM-wP vaccination induced a significant increase of
anti-Bp IgM in the serum 1-week post-booster vaccination (Fig. 15A). IM-wP, IM-aP, and
IN-aP vaccinated rats had a significant increase in anti-Bp IgG antibody titers following
booster immunization compared to mock vaccinated challenged (MVC) rats (Fig. 15B).
Rats vaccinated via IM-aP had a 100-fold significant increase in anti-PT IgM antibody
titers one week post booster vaccine, compared to the MVC control (Fig. 15C). IM-aP
and IN-aP vaccinated rats had a significant increase in anti-PT IgM antibodies compared
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to IM-wP, and OG-aP vaccinated rats (Fig. 15C). This same trend was also observed in
measuring anti-PT IgG antibodies (Fig. 15D). Here our data show that following booster
immunization, IN-aP vaccinated rats developed systemic anti-Bp IgG and anti-PT IgG and
IgM antibody titers.

Mucosal vaccination protects against cough from Bp infected rats.
In 2014, Warfel et al showed that aP vaccination was protective against pertussis disease,
but failed to protect against colonization and transmission of Bp in the nonhuman primate
model (14). We hypothesized that mucosal vaccination with DTaP would protect against
Bp induced cough by eliciting a protective immune response at the respiratory mucosa.
To test this hypothesis, vaccinated rats were subsequently intranasally challenged with
Bp 2-weeks post-booster vaccine administration (Fig. S13). Every evening postchallenge, coughs were counted using whole-body plethysmography (WBP). MVC rats
averaged a total of five coughs or less during monitoring for the first 5 days of infection
(Fig. 16A). At days 6 and 7 post-challenge, average coughs per fifteen minutes increased
to more than thirty coughs (Fig. 16A). There was a significant decrease in coughs for rats
vaccinated with IM-wP, IM-aP, IN-aP, and OG-aP at days 6 and 7 post-challenge
compared to MVC rats (Fig. 16B-E). On average, rats vaccinated with IM-wP coughed
approximately 6 coughs per fifteen minutes each day (Fig. 16B). Rats vaccinated with
IM-aP on average coughed 2 times per fifteen minutes each day (Fig. 16C). IN-aP
immunized rats on average coughed 3 times per fifteen minutes each day, while OG-aP
vaccinated rats coughed on average 4 times per fifteen minutes each day (Fig. 16D&E).
To compare the average total number of coughs each day post-challenge, we calculated
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the total number of coughs for each group per animal. We observed a significant decrease
in total number of coughs in rats vaccinated with IM-aP (14 coughs) and IN-aP (27
coughs) compared to MVC rats (102 coughs) over the nine-day infection (Fig. 16F). OGaP immunized rats coughed on average 35 times (Fig. 16F). Our data demonstrates that
mucosal vaccination in rats protects against Bp induced cough.

Intranasal vaccination protects against pulmonary distress.
Our previous work has shown that Bp infected rats had a significant increase in pulmonary
distress following challenge (43). Pulmonary distress can be evaluated by calculating
enhanced pause (PenH). PenH functions as a representation of bronchoconstriction
taking into consideration the timing between early and late expiration and the estimated
maximum inspiratory and expiratory flow per breath. We hypothesized that mucosal
vaccination would protect against Bp induced pulmonary distress, as bacterial clearance
would decrease inflammation. Here, rats vaccinated with IM-wP, IM-aP, and IN-aP had a
significant decrease in PenH compared to the MVC control group at days 5 and 7 postchallenge (Fig. 17A-D). Rats vaccinated IM-aP and IN-aP also had a significant decrease
in PenH at day 6 post-challenge compared to MVC rats (Fig. 17A&C-D). However, there
was no significant decrease in PenH in OG-aP vaccinated rats compared to MVC
suggesting that the induced immune response is not sufficient enough to protect rats from
Bp induced respiratory distress (Fig. 17E). Other respiratory parameters were also
measured using WBP (Fig. S14). In brief, we observed that rats vaccinated IM-wP, IMaP, and IN-aP had a significant decrease in pause (PAU) compared to MVC control group,
which is another indicator of bronchiole restriction (Fig. S14B). Rats vaccinated with the
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aP regardless of route also had a significant decrease in Tidal volume (TVb) compared
to MVC rats, which could be crudely associated with inflammation (Fig. S14D). Overall,
our data demonstrated that IN-aP vaccination decreases pulmonary distress of Bp
infected rats.

Mucosal immunization induces production of Bp specific antibodies in the serum,
while intranasal immunization also induces PT specific antibodies in the serum.
Next, we wanted to measure systemic antibody responses to Bp and PT following
challenge. IM-wP vaccinated rats had a slight increase in anti-Bp IgM antibodies
compared to all other vaccinated groups, albeit not significant (Fig. 18A). We observed a
significant increase in anti-Bp IgG antibody titers in IM-wP, IM-aP, and IN-aP vaccinated
rats compared to the MVC at day 1 post challenge (Fig. 18B). At day 9 post-challenge,
all vaccinated rats had a significant increase of anti-Bp IgG antibody titers compared to
the MVC control (Fig. 18B). Following Bp challenge, IM-aP and IN-aP immunized rats
had a significant increase in anti-PT IgM antibodies compared to IM-wP immunized rats
and MVC control. (Fig. 18C). Similar results were observed in measuring anti-PT IgG
titers (Fig. 18D). IM-aP and IN-aP vaccination induced a significant increase in anti-PT
IgG antibody titers compared to MVC, IM-wP, and OG-aP immunized rats after booster
vaccination and at days 1 and 9 post-challenge (Fig. 18D). Although not significant, two
of the OG-aP immunized rats had detectable anti-PT IgG antibody titers in the serum at
day 9 post-challenge (Fig. 18D). Enzyme-linked immune absorbent spot (ELISpot) assay
was used to determine the number of Bp specific IgG cells in the bone marrow at day 9
post-challenge. There was an increase in the number of Bp specific IgG cells in the bone
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marrow in all vaccination groups compared to the MVC control; however, the only
significant increase in Bp specific IgG producing cells in the bone marrow was detected
in IM-wP vaccinated rats (Fig. S15). Our data indicate that mucosal vaccination via IN
and OG immunization induced Bp specific IgG antibody responses.

Intranasal immunization induces production of Bp specific IgA antibodies in the
nasal cavity
In humans, previous Bp infection leads to anti-Bp IgA antibodies in nasal secretions (18).
IgA antibodies to Bp play a role in the inhibition of Bp attachment in vitro to epithelial cells
(19). Here, we investigated if IN and OG immunization of DTaP would induce mucosal
IgA antibodies in the lung and/or the nasal cavity. In the lung, three of the four IN-aP
vaccinated rats had detectable anti-Bp IgA antibodies at day 1 post-challenge, although
not significant (Fig. 19A). We did not detect anti-Bp IgA antibody titers at day 1 postchallenge in the lung of IM-wP, IM-aP, or OG-aP vaccinated rats (Fig. 19A). Low levels
of anti-Bp IgA titers were measured in all vaccinated groups at day 9 post-challenge albeit
not significant compared to our MVC control (Fig. 19A). The same trend was observed in
the lung measuring anti-PT IgA titers at day 1 post-challenge (Fig. 19B). At day 9 postchallenge 50% of IN-aP rats and 25% of rats OG-aP vaccinated had detectable anti-PT
IgA (Fig. 19B). In the nasal cavity, only one IN-aP vaccinated rat had detectable anti-Bp
IgA antibody titers; however, we did measure a significant increase in anti-Bp IgA
antibodies in IN-aP immunized rats at day 9 post-challenge compared to the MVC, IMwP, IM-aP, and OG-aP immunized rats (Fig. 19C). Only one IN-aP and one OG-aP
vaccinated rat had detectable amounts of anti-PT IgA in the nasal cavity at day 9 post

124

challenge (Fig. 19D). Overall, our data reveal that IN-aP immunization is capable of
inducing IgA antibodies in the nasal cavity of rats.

Mucosal immunization protects against acute inflammation in the lung.
Our previous rat challenge study illustrated that intranasal Bp challenge gave rise to both
acute and chronic inflammation in the rat lung (43). Here, we used histology to assess if
mucosal immunization would protect against Bp induced inflammation in the lung. At day
1 post-challenge, no differences in acute inflammation were observed; however, at day 9
post-challenge, rats vaccinated with IM-aP, IN-aP, and OG-aP had a significant lower
acute inflammation scoring compared to the MVC rats. (Fig. 20A&C). IN-aP immunized
rats had a higher chronic inflammatory score at day 1 post-challenge (Fig. 20B&D). There
were no observed differences in chronic inflammation in vaccinated rats compared to
MVC rats at day 9 post-challenge (Fig. 20D). Total inflammation was calculated by
combining both acute and chronic inflammatory scores, as rat lungs exhibited both types
of inflammation. No differences in total inflammation score were observed at day 1 postchallenge; however, all vaccinated rats had a significant lower total inflammation score
compared to MVC rats (Fig. 20E). There were no differences in lung weight, which can
be used as a crude measurement for lung inflammation, following Bp challenge. (Fig.
S16A). We did observe a significant increase in percent body weight change in IM-wP
vaccinated rats compared to MVC control rats suggesting that wP protects against weight
loss observed in non-vaccinated challenged rats (Fig. S16B). Our observations suggest
that that mucosal vaccination protects against Bp induced inflammation in the lung (Fig.
20C&E).
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Mucosal vaccination protects against Bp challenge.
Next, we wanted to assess if mucosal immunization could protect against Bp burden in
the respiratory tract. Bacterial burden in the respiratory tract was determined 1hr, 1-, and
9- days post Bp challenge. Bacterial burden was measured at 1hr post-challenge (n=2)
to assess potential bacterial loss for our original challenge dose. In the lung, trachea, and
nasal lavage fluid, we measured approximately 106 CFUs 1hr post challenge (Fig. 21AC). At day 1 post-challenge there was a significant 98.5% reduction in bacterial burden in
the lung of IM-aP immunized rats compared to MVC (Fig. 21A). IM-wP. IM-aP, IN-aP,
and OG-aP vaccinated rats all had a significant decrease in bacterial burden in the lung
at day 9 post-challenge compared to MVC rats (Fig. 21A). There was also a significant
decrease in bacterial burden in the trachea at both days 1 and 9 post-challenge in all
vaccinated rats compared to MVC (Fig. 21B). At day 1 post-challenge, there was a
significant 86-97% reduction in bacterial burden in all vaccinated rats compared to MVC
rats in the nasal cavity (Fig. 21C). At day 9 post-challenge we did not measure any
significant differences between groups as most of the bacteria were cleared from the
nasal cavity (Fig. 21C). Overall, we observed that IN-aP and OG-aP vaccinated rats have
a significant reduction in bacterial burden in the respiratory tract compared to the MVC
control group at days 1 and 9 post-challenge (Fig. 21A-C).

wP immunization induces a proinflammatory cytokine response compared to
mucosal vaccinated Sprague-Dawley rats.
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Previous studies have shown that both wP immunization and Bp infection induces a proinflammatory Th1/Th17 immune response, while aP immunization promotes a more Th2
skewed response (44–50). In our current study, we measured cytokines in the lung and
serum induced from vaccination and challenge. In the lung at day 1 post-challenge, we
measured a significant 4-fold increase in IL-17 in MVC rats compared to IM-aP and INaP vaccinated rats (Fig. 22A). At day 9 post-challenge, IM-wP immunized rats had a
significant increase in IL-17 compared to IM-aP, IN-aP, and MVC rats (Fig. 22A). IM-wP
vaccinated rats also had a significant increase in Th1 cytokine IL-12p70 compared to
MVC rats in the lung and serum at day 9 post-challenge (Fig. 22A&B). IM-wP vaccinated
rats had a significant increase in Th2 cytokines IL-4 and IL-13 in the serum compared to
IM-aP and IN-aP vaccinated rats and a significant increase in IL-4 to MVC control at day
9 post-challenge (Fig. 22B). IM-wP immunized rats also had a significant increase in GCSF in the serum day 9 post-challenge compared to IM-aP, IN-aP, OG-aP, and MVC
rats. Overall, we did not observe marked changes in cytokine responses between DTaP
vaccinated rats compared to the MVC control group; however, rats OG-aP immunized did
have a slight increase in IL-17, though not significant. The observed difference in
cytokines levels could be from Bp challenge rather than vaccination. The increase in
acute inflammatory score in the lung of IM-wP immunized rats at day 9 post-challenge
could be associated to the increase in proinflammatory cytokines. Graphs showing the
statistical significance between cytokines in the serum and lung are in the supplementary
data (Fig. S17&18). Our data support that response to B. pertussis in IM-wP immunized
animals is associated robust cytokine response compared to both naïve and aP
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vaccinated rats, which is to be expected based on the work that has examined the Th17
response induced by whole cell pertussis vaccines.

Bp infection induces an increase in circulating neutrophils in the blood, as well as white
blood cells and lymphocytes (51–56). In our current study, we utilized hematology and
flow cytometry to evaluate these populations. Hematology analysis revealed a significant
increase in blood lymphocytes in the IN aP vaccinated rats compared to MVC postchallenge; however, no other differences in white blood cell counts in the blood were
observed in the other vaccinated groups. (Fig. S19A&B). At day 1 post-challenge, there
was a significant decrease in circulating neutrophils in the blood for IN-aP immunized rats
compared to MVC rats (Fig. S19C). Flow cytometry analysis observed minimal
differences in the number of neutrophils and B cells at days 1 and 9 post-challenge in all
groups (Fig. S19E&F). Based upon these data, subtle differences in various circulating
cell populations were observed following IN-aP vaccination.

Serological responses correlate with bacterial clearance in the respiratory tract.
Currently no definitive correlates of protection (CoP) for vaccines to protect against Bp
have been established (22). It is appreciated that Th17 responses as well as Trms
correlate with strong protection in mice and baboons. Antibodies to PT/FHA/PRN do not
always correlate with protection in humans.

In an effort to more precisely define

correlates, using the rat model, we aimed to utilize the coughing phenotype and bacterial
burden to identify the nature of how each vaccine protects (OG/IN/IM; acellular or wP).
Previous work in our lab performed by Wolf et al (2021) illustrated that serum anti-Bp,
anti-FHA, and anti-PT IgG antibody titers in the serum following IN vaccination in mice
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correlate with the decrease in bacterial burden in the lung following Bp challenge (28).
Previous studies have shown that serum anti-Bp IgG antibodies induced from wP
vaccination correlate with protection against bacterial burden in the lung of Bp challenged
mice (57). Here, we hypothesized that antigen specific serum IgG and mucosal IgA
antibodies correlate with decreased bacterial burden and cough, as IN-aP and OG-aP
vaccination induced systemic and mucosal antibody responses. To test this hypothesis,
we generated correlograms to evaluate both negative and positive correlations elicited by
each vaccination route (58). Correlograms are an analysis tool that can be used to
determine if the relationship observed between variables (i.e. bacterial burden and
antibody titers) is random or not (59). If the relationship between the two variables is
random the R2 correlation value is or near zero (59). The relationship is considered
correlative if the R2 values approximately positive or negative one (59). Significant
positive nonzero correlation values demonstrate a positive correlation between variables,
while significant negative nonzero values represent a negative correlation (59). Negative
correlations are observed when two variables are inversely related to one another; that
is, when one variable increases, the other decreases. With these data, as bacterial
burden would drop, then the correlate would increase (negative correlation; inverse). A
positive correlation would mean that as bacterial burden increases so does the correlate
that is being compared to.

IM-wP vaccinated rats had strong negative correlations (protective) between serum antiBp IgG antibodies to both bacterial burden in the lung (R2= -0.97) at day 1 post challenge
and the nasal cavity (R2 = -0.84) at day 9 post-challenge (Fig. 23A-B). At day 1 post-
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challenge, we observed negative correlations (protective) between systemic anti-Bp IgM
and anti-PT IgG antibodies in IM-aP vaccinated rats to bacterial burden in the nasal cavity
(R2 = -0.64, -0.64 respectively).

Additionally, negative correlations were observed

between anti-Bp IgM antibodies and bacterial burden in the trachea (R2 = -0.72) at day 9
post-challenge (Fig. 23C-D). IM-aP vaccinated rats also had negative correlation
between total cough counts over the course of challenge with IgG and IgM antibodies to
Bp and PT (Fig. 23D). We expected that IN immunization would induce negative
correlations between both serum- and mucosal-specific antibodies compared to bacterial
burden in the lung, trachea, and nasal cavity at day 1 post-challenge (Fig. 23E). Lung
anti-Bp IgA antibodies also negatively correlated with total cough count (R2 = -0.74) and
bacterial burden (R2 = -0.6) in the lung at day 9 post-challenge for IN-aP vaccinated rats
(Fig. 23F). We observed strong negative correlations between serum IgG and mucosal
IgA antibody to bacterial burden in the lung (R2 = -0.93, -0.93 respectively) in OG-aP
vaccinated rats at day 1 post-challenge despite the overall lower serological responses
(Fig. 23G). At day 9 post challenge, there was a negative correlation between serum antiBp IgG antibodies to bacterial burden in the lung (R2 = -0.81), trachea (R2 = -0.49), and
nasal cavity (R2 = -0.52) in OG-aP immunized rats (Fig. 23H). We also noticed that OGaP vaccinated rats had negative correlations between serum IgG and mucosal IgA
antibodies in the lung to total cough count (R2 = -0.94, -0.84) at day 9 post-challenge (Fig.
23H). Positive correlations (non-protective) were observed between bacterial burden and
total inflammatory score in IM-wP, IM-aP, and OG-aP immunized rats (Fig. 23A, C, G).
Bacterial burden also positively correlated with total cough counts at day 9 post challenge
(Fig. 23B, D, F, H). By utilizing correlograms, strong negative correlations between serum
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serological responses and bacterial burden were observed in IM-wP and IM-aP
immunized rats. Additionally, our data underscore the idea that both systemic and
mucosal antibodies correlate with the observed Bp clearance in the respiratory tract and
protection from Bp induced cough elicited from IN-aP and OG-aP vaccination highlighting
the observed differences between vaccination routes.

3.4 Discussion
The immunity induced by aP vaccines is relatively short lived; thus, DTaP/Tdap
vaccinated individuals are still capable of Bp transmission (60, 61). We have recently reinvestigated the rat model of pertussis to further understand Bp pathogenesis from current
circulating Bp strains (such as CDC isolate D420) (43). The coughing rat model of
pertussis is a tool that can be used to evaluate bacterial burden in the respiratory tract,
and also evaluate vaccine-induced immunity against cough and respiratory function (36–
41, 62). In our current study, we evaluated mucosal vaccination with DTaP in the coughing
rat model of pertussis. To our knowledge, this study is the first to evaluate both IN and
OG administered DTaP in the coughing rat model of pertussis. The data presented here
suggest that, not only does mucosal immunization protect against bacterial burden, but
also against Bp induced cough by WBP (Fig. 16&21).

Vaccine mediated immunity has been studied in the coughing rat model of pertussis.
Utilizing audio tape recorders, Hall et al (1998) illustrated that 3 and 5 component aP
vaccines administered subcutaneously could protect against Bp induced cough (41). wP
immunization administered intraperitoneally also decreased the incidence of cough in rats
(39). Neither study noted protection against bacterial colonization. Here, in our study,
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WBP was used to investigate Bp induced cough in IN-aP and OG-aP vaccinated rats, as
well as measure bacterial burden in the respiratory tract. Our data supports that mucosal
administration of DTaP protects against bacterial burden in the respiratory tract and
reduced Bp-induced cough (Fig. 16&21). In addition, IN-aP vaccination reduced bronchial
constriction in the lung that is elicited by Bp infection (Fig. 18).

Previous studies

evaluating wP and aP vaccines in the rat model of pertussis used one human dose per
rat for immunization prior to challenge (39, 41). In an effort to best model an appropriate
human to rat dose, we utilized a 1/5th human dose to prime and boost based on the
relative sizes of rats compared to mice.

We have reported 1/40th human dose as

protective in mice and rats are roughly 10x the weight of mice (63). One caveat of this
study is that we did not evaluate other human-to-rat titrations of aP. Identification of a
minimal protective rat dose would allow for the investigation of vaccine efficacy of new
potential antigens/adjuvants in this model (63).

Mucosal immunization has been of particular interest in the pertussis field. We and others
have recently evaluated intranasal immunization of DTaP in Bp challenged mice (27, 28,
64–66). Intranasally DTaP vaccinated mice were protected against Bp challenge and also
generated both systemic and mucosal antibodies (27, 28). Live attenuated strain BPZE1
administered intranasally was protective against Bp challenge in mice and baboons, and
is currently in Phase 2 of clinical studies (33, 34, 67, 68). BPZE1 immunization induces
both anti-Bp IgG and IgA antibodies systemically and has an increase in resident memory
T cells in the lung (33, 69). Oral immunization has also been investigated as a possible
vaccination strategy against pertussis. Oral immunization of heat-inactivated Bp
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protected newborns against Bp challenge, as well as generated serum and saliva
antibody titers (70). Recombinant technologies has led to the development of live
attenuated Salmonella strains presenting Bp antigens (71, 72). Oral immunization of
Salmonella typhimurium aro vaccine strain harboring the gene for PRN resulted in
reduced bacterial colonization in the lung post Bp challenge (71). Salmonella dublin aroA
mutant expressing the gene for FHA was also orally administered as a vaccine in mice
(72). Vaccination with this strain induced IgG and IgA antibody titers to FHA in the serum
and gut (72). Our current study shows that mucosal immunization not only induced
systemic anti-Bp IgG but also anti-Bp IgA antibodies that likely play role in clearance at
the mucosa (Fig. 18-19, 21).

CoP is defined as the immune response that is statistically accountable for the observed
protection (73). While no CoP has yet to be fully agreed upon against pertussis in humans,
anti-PT IgG levels >5 IU/ml are associated with protection in humans (74). In mice, IN
administration of DTaP induced anti-Bp, anti-FHA, and anti-PT IgG antibodies while wP
vaccination induced serum anti-Bp IgG antibodies that correlated with protection against
Bp (28, 57). Here in our study, we generated correlograms between all vaccinated groups
to identify correlations between variables in the coughing rat model of pertussis, which
has yet to be established (Fig. 23). Our results indicate that bacterial clearance in the
lung, trachea, and nasal cavity negatively correlate with systemic anti-Bp and -PT IgM
and anti-Bp IgG antibodies in IM-wP and IM-aP immunized rats, while systemic and
mucosal antibodies correlated with bacterial clearance in IN-aP and OG-aP vaccinated
rats (Fig. 23). Antibodies generated following immunization also negatively correlated
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with a decrease in total cough counts in vaccinated rats (Fig. 23). These results suggest
that the increase in systemic and mucosal antibodies induced from IN and OG vaccination
correlates with protection against Bp burden in the respiratory tract and Bp induced
cough. It is important to note, that OG-aP immunized rats did not generate significant
serum antibody titers to the whole bacterium until day 9 post-challenge (Fig. 18B). Also,
two OG-aP immunized rats had an increase in anti-PT IgG antibody titers in the serum
and anti-Bp IgA antibodies in the lung (Fig. 18D, 19A). We did however detect antigen
specific B cells in the bone marrow and 3 of the 4 rats had low levels of IgA in the lung in
OG-aP immunized rats (Fig. S15). One caveat that should be mentioned is that we did
not investigate the T cell responses (Th1/Th2/Th17/Trm/Tem) in rats but future studies
will incorporate this into the study design. We have proposed a summary for mechanism
for oral vaccination of aP (Fig. S20). We hypothesize that this could be because limited
amount of vaccine that successfully travels to the gut-associated lymphoid tissue (GALT)
for the generation of an immune response. Oral vaccines have to travel through increased
pH in the stomach while limited absorption and availability for antigen recognition also
occur in the gastrointestinal tract (75). Increase in dose, number of doses, or delivering
vaccine in an encased vehicle are potential methods to increase orally vaccinated
immune responses. Targeting of vaccine to intestinal M cells for antigen presentation has
also been shown to increase oral vaccine efficacy (76). Though we did not study new
adjuvants here, we hypothesize adjuvants can aid in stimulating a protective mucosal
immune response. These approaches could all potentially increase the efficacy observed
through oral vaccination of aP. Furthermore, to deliver the vaccine to the gut, one could
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envision novel deliver mechanisms such as gelatin coated chewables similar to gummy
vitamins that are now popular.

In summary, mucosal vaccination not only protected against bacterial burden in the
respiratory tract of challenged rats, but also protected against Bp induced cough and
respiratory distress measured by WBP (Fig. 16-17, 21). It is critical that “next generation
pertussis” vaccines protect against bacterial colonization in the lung, nasal cavity, and
trachea, as disease manifestations are dependent on bacterial colonization of the lung
and trachea, mediated by FHA and fimbriae (77, 78). Both IN and OG immunized rats
generated anti-Bp specific IgG antibodies in the serum, while IN vaccinated also
generated significant anti-Bp IgA antibody titers in the nasal cavity following challenge
(Fig. 18-19). IN-aP and OG-aP immunized rats were protected against acute and total
inflammation in the lung (Fig. 20). Our data support the potential of a mucosal vaccination
against Bp.

Further work is needed to fully characterize the immune response generated following
IN-aP and OG-aP vaccination in rats, as well as vaccine mediated immunity from
vaccination in the coughing rat model of pertussis. T cell immune responses that have
been shown to play a role in natural and vaccine mediated immunity against pertussis
have yet to be evaluated in the coughing rat model of pertussis due to limited availability
of resources to adequately measure T cell responses. Vaccine mediated memory has
yet to be evaluated in the coughing rat model of pertussis. Additional research is needed
to critically assess vaccine mediated memory, as it is essential that next generation of
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pertussis vaccines induce longer lasting memory then current vaccines. Future work is
also needed to evaluate mucosal immunization against current circulating strains of Bp
as current strains are genetically divergent from strains of the past, with the goal of making
the most efficacious vaccine against Bp.

3.5 Materials and methods
Vaccine composition and administration. INFANRIX (GSK Cat. 58160-810-11)
acellular pertussis human vaccine (DTaP) and the National Institute for Biological
Standards and Control WHO whole cell pertussis vaccine (NIBSC code 94/532) was used
for this study. Vaccines were diluted with endotoxin-free Dulbecco’s PBS (Thermo Fisher
Scientific Cat. TMS012A) to a concentration of 1/5th human dose. Vaccines were diluted
and administered no more than 1 hr. from composition. The first dose of vaccine was
administered to three-week-old (50g) female Sprague-Dawley rats (Charles River Cat.
001CD). At six weeks of age, a booster vaccine of the same dose was administered,
followed by Bp challenge at eight weeks of age. Intramuscular (IM) vaccinated rats
received 100µl in the right thigh muscle of the hind limb. Intranasal (IN) immunized rats
were first anesthetized with isoflurane until breathing was minimal. Rats then received
50µl of vaccine in each nostril for a 100µl dose. Oral gavage (OG) vaccinated rats
received 100µl dose delivered curved 18 gauge feeding needle (Fisher Scientific Cat.
NC9349775). MVC control group received 100µl of the same endotoxin free PBS used to
dilute the vaccines in the right thigh muscles of the hind limb. One-week post-prime, twoweek post-prime, and one-week post-boost blood was collected via saphenous blood
draws for serological analysis. 5mm animal lancets (Fisher Scientific Cat. NC9891620)
was used for blood draw. Blood was collected in capillary tubes (Fisher Scientific Cat.
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NC9059691) for centrifugation. Blood was spun at 15,000x g for 3 min., serum collected
and stored at -80°C until analysis.

Bordetella pertussis strains and growth conditions. Bp strain D420 was cultured on
Bordet Gengou (BG) agar (RemelTM Cat. R45232) supplemented with 15% defibrinated
sheep blood (Hemostat Laboratories Cat. DSB500) (1). Bacteria cultured BG plates
incubated for 48 hrs at 36°C. Using polyester swabs (Puritan Cat. 22-029-574), Bp was
transferred into 20 ml Stainer-Scholte liquid media (SSM) in new 125 ml flasks (Thermo
Fisher Scientific Cat. FB500125) (79). Bacterial cultures were allowed to grow at 36°C for
24 hrs inside a shaking incubator at 180 rpm.

Intranasal challenge. Vaccinated eight-week-old ~200g female Sprague-Dawley rats
were then challenged. Bp was grown as illustrated above. Rats were anesthetized with
ketamine and xylazine 50-100/5-10 mg/kg and challenged with 108 CFUs in 100µl
intranasally, 50µl in each nostril. Body weight of each rat was recorded before bacterial
challenge, and body weights were taken post-euthanasia to calculate percent weight
change. At days 1 and 9 post challenge, rats were then euthanized. Upon euthanasia
blood was collected via cardiac puncture and transferred into ethylenediaminetetraacetic
acid (EDTA) (BD Cat. 365974) and serum separation (BD Cat. 026897) tubes. Following
cardiac puncture, 250µl of blood was collected into EDTA tubes for flow cytometry and
ProCyte (IDEXX) analysis, while remaining blood was collected in serum separation tubes
to isolate the serum via centrifugation (15,000x g for 3 min) and used for serological and
cytokine analysis. To determine bacterial burden in the respiratory tract, the lung and
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trachea was excised separately and homogenize. Lung weights were recorded following
excision before homogenization. Lungs were then collected in gentleMACS C tubes
(Miltenyi Biotec Cat. 130-096-334) in 2ml of PBS and homogenized using Miltenyi Biotec
tissue dissociator (Cat. 130-095-927). Polytron homogenizer was used to homogenize
the trachea in 1 ml PBS. Bacterial burden in the nares was determined by flushing 2mls
of sterile 1x PBS through the nares and collected for serial dilution and plating. Serial
dilutions of the homogenates and nasal collection were plated on BG plates
supplemented with ceftibuten (Sigma-Aldrich Cat. SML0037) 10 µg/ml.
Serological analysis. Enzyme-linked immunosorbent assays (ELISA) was used to
measure antibody titers of vaccinated and infected rats. Bp specific whole bacteria ELISA
plates were coated with 50 µl of 108 Bp grown as mentioned above for infection. Antigen
specific antibody titers to PT (List Biological Laboratories #180) were measured by
coating ELISA plates with 50 µl of antigen per well. Antigen coated plates incubated over
night at 4°C. After incubation, plates were washed with 1x PBS-Tween 20 and blocked
with 5% skimmed milk for 2 hrs at 37°C. Following blocking, ELISA plates were washed
and serum from the saphenous blood draws and blood collected from cardiac puncture
post-euthanasia were serially diluted down the ELISA plate and incubated for 2 hrs at
37°C. To measure respiratory IgA antibody titers in the lung and nasal lavages, lung
homogenate supernatant and nasal lavage was added and incubated for 2 hrs at 37°C.
After incubation, ELISA plates were washed as described above and 100µl of secondary
goat anti-rat IgG (SouthernBiotech Cat. 3030-04), goat anti-rat IgM (SouhternBiotech Cat.
3020-04), or goat anti-rat IgA (MyBioSource Cat. MBS539212) was added to the plates
at a dilution of 1:2,000 in PBS + 5% milk and incubated for 1 hr at 37°C. Plates were then
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washed again and 100 µl p-nitrophenyl phosphate substate (Thermo Scientific Cat.
37620) was added and the plate was developed for 30 min at room temperature. After
development, colorimetric signal of the ELISA plate at A450 was measured by a Biotek
Synergy H1 microplate reader. Antibody titers were considered positive if values were
higher than the baseline. Baseline value for each sample was set as double the average
value of the blank, in which no serum, lung supernatant, or nasal lavage added to these
well. Limit of detection was set at 50, and any samples with a titer value less than that
were set to 50.
ELISpot assay. ELISpot assay (ImmunoSpot Cat. mTgG-SCE-1M/2) was used to
analyze antigen specific B cells in the bone marrow. The right hind femur of the rat was
removed and placed into Dulbecco’s modified Eagle’s medium (DMEM) and frozen at 80°C until analysis. Bones were then thawed in water bath at 37°C, and immediately
transferred into spin tubes and spun at 1,000x g for 3 min to collect the bone marrow.
Bone marrow was passed through a 70µm filter to create a single cell suspension. Cells
were centrifuged at 350 x g for 5 min and the cell pellet was resuspended in CTL test B
Media (ImmunoSpot). D420 was cultured as described above and coated the 96-well
ELISpot plate as described by ELISA. The plate incubated overnight at 4°C. Plate was
then washed with 1x PBS before cells were added. Three serial dilutions of cells (1.25 x
106, 3.13 x 105, and 1.56 x 105) cells added per well and incubated at 37°C overnight.
Rabbit anti-Rat IgG antibody (Abcam Cat. ab6733) was used to replace the anti-murine
IgG detection antibody that was with the kit. The rest of the protocol was followed as per
the manufacturer’s instructions. ELISpot plates imaged and analyzed using ImmunoSpot
S6 Entry analyzer and CTL software.
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Analysis of cough and bronchiole restriction using whole-body plethysmography.
Buxco® FinePointeTM Whole Body Plethysmography (WBP) (DSI) was used to quantify
respiratory function during infection. Every day following Bp challenge and one day before
challenge (5:00PM), rat respiratory profiles and coughs were measured. A 5 min
acclimation period was used before measuring cough and other respiratory parameters.
After acclimation the respiratory profile was recorded for 15 mins for each rat. Coughs
were counted and represented over 15 mins. Enhanced pause (PenH) was calculated
which represents bronchiole restriction during breathing. Coughs were counted based on
box flow changes of the subject with classical cough-like waveforms. Patented fuzzy logic
criteria was used to detect and count coughs (80). Each cough in a multi-cough event
was counted individually. Frequency (F), Tidal Volume (TVb), Pause (PAU), Minute
Volume (MVb), Inspiratory time (Ti), and expiratory time (Te) were also collected and
analyzed during the course of infection.
Histological assessment of the lung. The left lobe of the lung was used for histological
assessment. Following excision of the left lobe, the sectioned portion was fixed in 10%
formalin 48 hrs at 26 °C. Following fixation, samples were embedded in paraffin and
stained with H&E by the WVU Pathology Department. Stained samples were used to
characterize and score inflammation of the lung. All scorings were done by a boardcertified pathologist (iHisto). Individual scores were based on a standard qualitative
scoring criterion: (0 – none, 1 – minimal (rare), 2 – mild (slight), 3 – moderate, 4 – marked,
5 –severe). The presence of neutrophils in the parenchyma, blood vessels, and airway
was used to score acute inflammation, and chronic inflammation was characterized by
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mononuclear infiltrates of the parenchyma, blood vessels, and airway. All examination
and scoring were done with no knowledge of the groups.
ProCyte analysis of blood. Blood from the EDTA tubes was used to analyze white blood
cell, neutrophil, and lymphocyte counts. 25-50µl of blood was drawn from the EDTA tubes
and analyzed by the Procyte. After ProCyte analysis the rest of the blood was used for
flow cytometry analysis.
Flow cytometry analysis. Blood samples were lysed with 1x Pharmylse buffer (BD
Biosciences Cat. 555899) for 20 min at room temperature. Blood samples were vortexed
periodically during the 20 min incubation. After lysis, cells were resuspended in RPMI +
10% FBS to neutralize the lysis buffer and centrifuged at 1,000g x 5. Cells were then
washed with the RPMI +10% FBS again. Cells were then resuspended in
1%FBS+PBS+5mM EDTA. Blood samples were then blocked with anti-CD32 (BD
Pharmingen Cat. 550270) antibody for 15 min at 4°C. After blocking, the cells were
labeled; CD45 Alexa flour 700 (Biolegend Cat. 202218), CD161 APC (Biolegend Cat.
205606), CD45R PE Cy7 (eBioscience Cat. 25-0460-82), His48 FITC (eBioscience Cat.
11-0570-82), CD43 PE (Biolegend Cat. 202812), and CD3 VioGreen (Miltenyi Biotec Cat.
130-119-125) (81). Samples were incubated 1 hr at 4°C in the dark. To prepare the lung
samples for flow cytometry, the lung homogenate was filtered through a 70 µm cell
strainer (BioDesign Cell MicroSives Cat. N70R). The suspension was centrifuged at 1,000
x g for 5 min. The pellet was resuspended in Pharmlyse buffer and incubated at 37°C for
2 min. After incubation, the cells were centrifuged at 1,000 x g for 5 min, lysis buffer
removed, and cells were blocked and labeled with antibody as described for blood
samples. Both blood and lung samples were centrifuged at 1,000 x g for 5 min and the
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pellets were resuspended in 0.4% paraformaldehyde and stored overnight at 4°C.
Samples were washed with 1x PBS+5mM EDTA+1%FBS and resuspended in 1x
PBS+5mM EDTA+1%FBS for analysis. Cell samples were analyzed on a LSR Fortessa
and samples were gated and analyzed using FlowJo v10.
Cytokine analysis. Lung homogenates were centrifuged at 19,000× g for 4 min and the
resulting supernatant was removed and stored at −80 °C until further analysis. Lung
supernatant and serum cytokines were measured using a ProcartaPlex Multiplex
Immunoassay kit: Th Complete 14-Plex Rat ProcartaPlex Panel (Thermo Fisher Scientific
Cat. EPX140-30120-901) per the manufacturer’s instructions. Cytokines with bead counts
less than 35 were invalidated.
Generation of correlograms. Correlograms were created using R Studio software.
Pearson correlation coefficients were calculated between each set of variables listed in
the master table and then illustrated in the representative plot for each vaccine route and
timepoint.

Statistical analysis. GraphPad Prizm 7 was used to analyze the data. The minimum
biological replicates for the challenge studies were three for MVC control group and four
rats per vaccinated groups. For statistical comparisons between vaccinated groups and
the MVC control group over the entire course of the infection, two-way analysis of
variance (ANOVA) was used with Dunnett’s post hoc test. One-way ANOVA was used
for comparison between vaccinated groups and MVC for an individual day or timepoint
with Dunnett’s post hoc test. Kruskal-Wallis test with Dunnett’s post hoc test compared
between groups for mucosal IgA comparisons. ROUT test was used to identify any
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potential outliers during cytokine analysis of the lung.
Data availability. Data requests for figures provided can be addressed to the
corresponding author.
Ethics statement. This challenge study was performed in accordance with our approved
protocol by West Virginia University Institutional Animal Care and Use Committee
(IACUC) protocol 1811019148.6.
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3.7 Figures

Figure 15. IN booster vaccination induces systemic anti-Bp and anti-PT antibody titers.
1 and 2 weeks post prime immunization and 1 week post boost blood was collected via
saphenous vein, and anti Bp and anti PT IgM (A-C) and IgG (B-D) specific antibodies
were measured. Results are shown on a log scale and as a mean ± SEM (n = 3-8). Dotted
line represents the limit of detection. *P < 0.05. (n = 4-8). P values were determined by
two-way ANOVA with Dunnett’s post hoc test compared between groups. * under each
graph annotates the significance between labeled group under the y-axis and the group
under the corresponding bar. Grayed out box annotates no stats calculated.
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Figure 16. Intranasal and oral vaccination of acellular pertussis vaccine decreases cough
of B. pertussis infected rats. Coughs were counted every day of the nine-day infection
using whole body plethysmography. Coughs were counted for (A) mock vac. challenge
rats, (B) IM-wP (C) IM-aP (D) IN-aP, and (E) OG-aP, vaccinated and challenged rats. To
assess any potential differences between vaccine groups over the entire course of
infection, (F) average total number of coughs for each rat per group was compared.
Results shown as mean ± SEM (n = 3-4). P values were determined by two-way ANOVA
with Dunnett’s post hoc test and one-way ANOVA with Dunnett post hoc test for total
cough count, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared to the mock
vac. challenged control group.
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Figure 17. Intranasal vaccination decreases pulmonary restriction of Bordetella pertussis
infected rats. Bronchiole restriction was measured over the course of infection by whole
body plethysmography. Bronchiole restriction was determined by the factor Penh for (A)
mock vac. challenge rats, (B) IM-wP (C) IM-aP (D) IN-aP, and (E) OG-aP vaccinated and
challenged rats. Results shown as mean ± SEM (n = 3-4). P values were determined by
two-way ANOVA with Dunnett’s post hoc test, *P < 0.05, **P < 0.01, ***P <0.001
compared to the mock vac. challenge group.
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Figure 18. Mucosal vaccination induces production of anti-Bp IgG, while IN immunization
also induces both anti-PT IgM and IgG antibodies. ELISAs were used to determine and
compare the induced serological responses from vaccinated and challenge rats in the
serum. Both (A, C) IgM and (B, D) IgG serum antibody titers from immunized and
challenged rats were measured post prime, boost, and challenge. Dotted line represents
the limit of detection. Results are shown on a log scale and as mean ± SEM, *P< 0.05
(n = 4). P values were determined by two-way ANOVA with Dunnett’s post hoc test
compared between groups. * under each graph annotates the significance between
labeled group under the y-axis and the group under the corresponding bar. Grayed out
box annotates no stats calculated.
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Figure 19. Intranasal immunization elicits the production of anti-Bp IgA in the respiratory
tract. ELISA was used analyze antibodies in the (A, B) lung and (C, D) nasal cavity from
lung homogenate supernatant and PBS flushed through the nasal cavity from vaccinated
and challenge rats at days 1 and 9 post challenge. IgA titers were determined against
pertussis toxin and B. pertussis. Dotted line represents the limit of detection. Results are
shown on a log scale and as a mean ± SEM (n = 3-4). **P < 0.01, ****P < 0.0001 P values
were determined by Kruskal-Wallis test with Dunnett’s post hoc test compared between
groups.
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Figure 20. Mucosal vaccination protects against acute and total inflammation in the lung
of Bp infected Sprague-Dawley rats. Post euthanasia, left lobe of the lung was excised,
sectioned, and stained with hematoxylin and eosin. Lung samples scores were based on
standard qualitative toxicologic scoring criteria (0 – none, 1 – minimal (rare), 2 – mild
(slight), 3 – moderate, 4 – marked, 5 –severe). (A) Representative image of acute
inflammation of rat lung showing increased numbers of neutrophils and edema
surrounding blood vessel (asterisk). (B) Representative image of chronic inflammation of
the rat lung showing increased numbers of mononuclear cells surrounding bronchioles
(asterisk). Inflammatory cells are also present in the lamina propria (arrow) and epithelium
(arrowhead) of bronchioles. (C) Average acute inflammation scores of the lung are
detailed by the presence of neutrophils in the parenchyma, blood vessels, and the
airways. (D) Average chronic inflammation scores are distinguished by mononuclear
infiltrates in the parenchyma, blood vessels, and airway of the lung. (E) Total inflammatory
score calculated by the sum of the acute and chronic inflammation score of the lung. All
150

scoring assessments were determined with no knowledge of the groups. Results are
shown as mean ± SEM (n = 3-4) P values were determined by two-way ANOVA followed
by Dunnett’s comparison test, *P < 0.05, **P < 0.01 compared to mock challenge.
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Figure 21. Oral and intranasal immunization decreased B. pertussis bacterial burden in
the respiratory tract. Bacteria were quantified by serially diluted CFUs following
vaccination and intranasal challenge. CFU counts were determined from (A) lung
homogenate (B) trachea and (C) nasal lavage 1.5Hr, 1-, and 9-day post B. pertussis
challenge. Results are shown as mean ± SEM (n = 2-4). P values were determined by
one-way ANOVA with Dunnett’s post hoc test, *P < 0.05, **P < 0.01, ***P<0.001,
****P < 0.0001 compared to mock vac. challenge group.
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Figure 22. Measurement of cytokines in the lung and serum at days 1 and 9 post
infection. Heat map of the average percent cytokines normalized to the max cytokine
measured in the (A) lung and (B) serum. MVMC (mock vaccinated mock challenge)
cytokines are from rats in (Hall et al 2021). All statistical analysis comparing average
cytokine values are in Fig S5-6.
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Figure 23. Systemic and mucosal anti-Bp and anti-PT antibodies correlate with observed
protection. Correlograms were generated using the observed data for IM-wP (A-B), IMaP (C-D), IN-aP (E-F), and OG-aP (G-H). Program R was used to make correlation
graphs from raw data for both day 1 and day 9 post-challenge. R2 values were generated
when generating the correlograms. Positive correlations are annotated by the blue circles,
while the negative correlations are annotated by the red circles. The size of the circle
annotates the strength of the correlation.
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3.8 Supplemental Figures

Vaccination
Saphenous blood collection
Serological analysis
Whole body plethysmography
Flow cytometry analysis
Cytokine analysis
IgG specific ELISpot
Lung histology

Hematology analysis
Bacterial burden

Figure S 13. Experimental design of vaccination and challenge. Three-week old Sprague
Dawley rats were vaccinated IM-wP, IM-aP, IN-aP, and OG-aP 1/5th human dose. 21
days post prime, rats were boosted with the same corresponding vaccine. At days 7, 14,
and 28 post prime, blood was collected via saphenous blood draw for serological analysis.
At day 35, rats vaccinated rats were intranasally challenged with 108 viable Bp. Cough
and respiratory distress was measured using whole body plethysmography for 8 days
post challenge. Antibody titers in the serum, lung, and nasal cavity was measured at days
1 and 9 post challenge. Flow cytometry was used to measure neutrophil and b cell
recruitment in the lung and blood at days 1 and 9 post challenge. The left lobe of the lung
was sectioned and stained with H&E for analysis of inflammation at days 1 and 9 post
challenge. Antigen specific IgG ELISpot assay was performed to measure antigen
specific B cells in the bone marrow at days 1 and 9 post challenge. Cytokines in the lung
and serum were measured post challenge. Hematology was used to measure blood cell
populations post challenge. Bacterial burden in the respiratory tract was measured at
days 1 and 9 post challenge. Created with Biorender.com
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Figure S 14. Respiratory profile of Sprague-Dawley rats vaccinated and challenged with
B. pertussis. Every day after 5p.m. whole body plethysmography was used to analyze the
respiratory capacity of immunized and challenge rats. Measurements assessed were: (A)
frequency of breathes, (B) pause (PAU), (C) minute volume (MVb), (D) tidal volume (TVb),
(E) time of inspiration (Ti), and (F) time of expiration (Te). Results shown as mean ± SEM
(n = 3-4). P values were determined by two-way ANOVA with Dunnett’s post hoc test,
156

*P < 0.05, **P < 0.01, ***P<0.001, and ****P < 0.0001 compared to mock vac. challenge
group.
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Figure S 15. ELISpot assay was performed to measure the number of Bp specific IgG
cells from the bone marrow at day 9 post challenge. Results are shown as mean ± SEM
(n = 3-4). P values were determined by one-way ANOVA with Dunnett’s post hoc test,
*P < 0.05 compared to mock vaccinated challenge group.
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Figure S 16. Measurement of lung and body weight at days 1 and 9 post challenge. (A)
Lung weight as measured immediately after euthanasia before being homogenized. Body
weight for each rat was measured before challenge and immediately post euthanasia. (B)
Percent weight change was calculated by taking the differences between starting weight
and end weight and dividing by the initial weight multiplying by 100. Results shown as
mean ± SEM (n = 3-4). P values were determined by two-way ANOVA with Dunnett’s
post hoc test, *P < 0.05 compared to the mock vaccinated challenge group.
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Figure S 17. Measurement of cytokines in the lung at days 1 and 9 post infection.
Cytokines in the lung supernatant were analyzed using ProcartaPlex multiplex
immunoassay kit. Results shown as mean ± SEM (n = 3-4). P values were determined by
two-way ANOVA with Dunnett’s post hoc test, *P < 0.05, **P < 0.01 compared between
mock vaccinated challenge and vaccinated challenge groups.
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Figure S 18. Measurement of cytokines in the serum at days 1 and 9 post infection.
Cytokines in the serum and lung supernatant were analyzed using ProcartaPlex multiplex
immunoassay kit. Results shown as mean ± SEM (n = 3-4). P values were determined by
two-way ANOVA with Dunnett’s post hoc test, *P < 0.05, **P < 0.01 compared between
mock vaccinated challenge and vaccinated challenge groups.
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Figure S 19. Characterizing circulating cell populations in the blood and lung post
infection. ProCyte hematology analyzer was used to assess (A) total white blood cells,
(B) percent lymphocytes and (C) percent neutrophils in the blood post challenge.
Flowcytometry analysis of circulating B cells and neutrophils in the lung and blood. (D&E)
Neutrophils were gated by (CD45+ CD161- B220- CD43+ His48hi), while (F) B cells were
gate by (CD45+ CD45R+). Neutrophil and B cell quantification represented as percentage
of single, CD45+ cells. Results are shown as mean ± SEM (n = 3-4). P values were
determined by two-way ANOVA followed by Dunnett’s comparison test,

*

P < 0.05,

compared between mock vaccinated challenge group.
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Figure S 20. Proposed mucosal immune response induced through oral vaccination.
Upon oral vaccination of DTaP, antigens travel to the gut associated lymphoid tissue.
Here, antigens are endocytosed by M cells or phagocytosed by DCs in the epithelial layer
and antigens are presented to T and B cells in the lamina propria. Ensuing germinal center
reaction occur in lymphoid follicles and induce Bp specific plasma cells capable of
producing IgG and IgA antibodies. Generated plasma cells can home to secondary
lymphoid tissue and travel to the bone marrow awaiting recall. Upon Bp challenge, plasma
cells are recalled and migrate to the respiratory mucosa secreting IgG and IgA antibodies.
Here antibodies can opsonize the bacteria and potentially play a role in antibody mediated
phagocytosis of the bacteria with recruited neutrophils and macrophages. Other potential
mechanism for the generation of antibody secreting plasma cells involves direct class
switching and terminal differentiation.
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4.1 Overview
As highlighted in chapter 1, humans are the only reservoir for Bp, making it difficult for the
generation of an ideal animal model to study pertussis. Here, we wanted to reinvestigate
the coughing rat model of pertussis due to the similarities in clinical manifestations of
pertussis as in humans and utilize this model to evaluate mucosal immunization of DTaP.
In chapter 2, we focused on building upon the coughing rat model of pertussis utilizing
current techniques and resources. We detailed the hallmark manifestations of pertussis
such as paroxysmal cough, respiratory inflammation, and neutrophilia between two
genetically diverging strains. To our knowledge, this is one of the first studies to utilize
and establish WBP to precisely count cough and analyze respiratory distress of rats
following Bp challenge. We also carefully detailed the serological response to Bp
associated virulence factors such as FHA, PT, PRN, and ACT. Furthermore, we reported
that IN inoculation of Bp more uniformly colonized the respiratory tract compared to IB
inoculation that relies on high bacterial loads in the lung only. With the current circulating
isolates being genetically different from strains of the past, it is critical for the evaluation
of a new model to be as relevant and current as possible. As chapter 2 focused on further
developing the coughing rat model of pertussis, in chapter 3, we tested the vaccine
efficacy of mucosal vaccination of DTaP compared to IM administration of DTP and DTaP
utilizing the coughing rat model of pertussis. To our knowledge, this is one of the first
studies to investigate mucosal immunity against pertussis in rats. WBP was used to
determine if both IM and mucosal vaccination was protective against Bp induced cough
and respiratory distress. Serological responses following prime immunization, booster
vaccination, and following challenge were also characterized. Our results show that
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mucosal vaccination of DTaP is protective against Bp colonization of the respiratory tract
and protective against Bp induced cough.

4.2 Lessons learned from the coughing rat model of pertussis
As discussed in chapter 1, multiple animal models have been tested and have been
fundamental in our understanding of pertussis. A total of nine publications to date have
detailed using rats as a model to investigate either Bp pathogenesis or DTP/DTaP
vaccine efficacy (1–9). The last study utilizing the coughing rat model of pertussis was
performed in 1999 (9). Since 1999, we have observed cyclic increases in the number of
pertussis cases (Chapter 1. Fig. 5) (10). Pertussis resurgence combined with genetic
divergent strains call for reevaluation of our current animal models of pertussis to
understand Bp pathogenesis as it relates to humans, and the development of next
generation pertussis vaccines. Rats, as a model of pertussis present with Bp colonization
in the respiratory tract, leukocytosis, neutrophilia, pulmonary inflammation, and Bp
induced paroxysmal cough (1–9).

One of the aims of chapter 2 was to revitalize the coughing rat model of pertussis using
IN inoculation of a relatively current circulating isolate. Rats were IN challenged with Bp,
as IN inoculation deposits bacteria in both the upper and lower respiratory tract, which is
similar to bacterial placement in adolescent and adults with pertussis, rather than IB
inoculation that places the bacteria specifically in the lower area of the lung (11).

IN

challenge places the bacteria in the nasal cavity, trachea, and lung. IN instillation was
selected as the route of infection for its simplicity and control of the bacterial challenge
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dose. In mice, aerosol Bp challenge has been investigated and studies have shown that
aerosol challenge results in consistent bacterial loads in the respiratory tract following
challenge, and the rate of bacterial clearance and protection observed in vaccinated and
challenge mice was similar to vaccine efficacy in children (12, 13). Aerosol challenge was
selected for its naturality of infection as it relates to transmission of Bp in humans. Aerosol
challenge has yet to be investigated in the coughing rat model of pertussis, future studies
comparing routes of infection could further illuminate other pathogenic differences such
as cough, respiratory distress, and bacterial burden.

We IN challenged Sprague-Dawley rats with 108 CFUs of Bp stains Tohama 1 and
representative clinical isolated D420 (Chapter 2. Fig. 5). Strain D420 is genetically similar
to 50% of isolates that have been recovered across the United States in 2000 (14).
However, further challenge studies are needed to fully assess the impact of the observed
genetic divergence on pathogenesis of more current circulating strains. Our data showed
that IN Bp challenge resulted in bacterial burden in the nasal cavity, trachea, and lung
(Chapter 2. Fig. 11). We did measure an increase in bacterial burden in D420 infected
rats in the lung and nasal cavity compared to Tohama 1 infected rats (Chapter 2. Fig.
11). Immunofluorescence of the nasal cavity also found Bp attached to cilia of the nasal
turbinates and NALT (Chapter 2. Fig. 12). Isolation and characterization of the immune
populations of the NALT could be of particular interest particularly in the induction of
germinal center formation.

Previous research measuring cough in the rat model of pertussis used sound-activated
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tape recorders (2). Here, we accurately measured cough and bronchial constriction using
WBP, for twelve days post-challenge. Isolated coughs were detected at days 1 and 2
post-challenge, with peak cough occurring at day 8 post-challenge (Chapter 2. Fig. 6).
Overall, rats challenged with D420 had an increase in the number of coughs over the
entire infection compared to mock challenge rats (Chapter 2. Fig. 6). The onset and peak
coughing that were detected was similar to the previous studies using IB Bp challenge in
rats (3). Peak cough measured in baboons occurred at day 4 post challenge (15).
Differences in bacterial challenge doses and size of the animal could potentially play a
role in the timing of cough. WBP confirmed that Sprague-Dawley rats challenged with Bp
have an impaired respiratory capacity (Chapter 2. Fig. 7). Furthermore, use of WBP
could further improve the baboon model of pertussis and potentially identify other
potential differences in cough and respiratory signatures. Histological analysis of the lung
illustrated an increase in neutrophil infiltration early during the infection followed by
infiltration of monocytes and macrophages around the bronchioles at day 9 post challenge
(Chapter 2. Fig. 8). We also measured an increase in lung weight for rats IN challenged
with Bp (Chapter 2. Fig. 9). Our data suggests that cellular inflammation could play a role
in the observed respiratory distress and Bp induced cough.

The second aim of this study was to detail serological responses following Bp challenge.
With the development of the next generation of pertussis vaccines, characterization of
serological responses has become essential in understanding vaccine mediated
immunity. To date, no studies investigating the serological responses in rats through IN
Bp challenge have been conducted. In chapter 2, antibody titers to Bp virulence factors
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were measured following challenge. D420 infected rats had a significant increase in antiBp IgM antibody titers, while no anti-Bp IgM antibodies were detected in Tohama 1
infected rats (Chapter 2. Fig. 14). Both Tohama 1 and D420 infected rats had an increase
in serum anti-Bp IgG antibody titers at day 12 post challenge; however, Tohama 1 infected
rats had a significant increase in anti-Bp IgG titers compared to D420 challenged rats
(Chapter 2. Fig. 14). D420 harbors the ptxP3 allele and research has shown that strains
harboring ptxP3 released more PT during growth in vitro compared to ptxP1 strains (16,
17). This could potentially explain the differences in IgG antibody titers, as studies have
shown that PT can suppress serological responses (18, 19). Minimal antibody titers were
detected to FHA following challenge and no antibody titers against PT and ACT were
detected in rats challenged with Tohama 1 and D420 (Chapter 2. Fig. 11). Our data goes
to show that minimal to no antibody titers were detected against PT, FHA, PRN, and ACT
following IN Bp challenge; however, by day 9-12 post-challenge detectable amounts of
anti-Bp IgM and IgG were measured.

4.3 Investigation into the mechanism of Bp induced cough
With the redevelopment of the coughing rat model of pertussis, mechanism behind Bp
induced cough can be explored. Rats and nonhuman primates are the only animal models
capable of reproducing paroxysmal cough following Bp challenge. As the rat model of
pertussis capitalizes on ease of use, animal availability, and minimal husbandry cost, this
model could be critical in the evaluation of mechanisms responsible for Bp induced cough.

Limited studies have reported mechanisms that may play a role in Bp elicited cough. Our
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data in both chapter 2 and chapter 3 showed that Sprague-Dawley rats cough upon IN
Bp challenge. Onset of cough occurred at day 2 post-challenge, with peak cough
occurring at days 8-10 post-challenge (Chapter 2. Fig. 6). One potential hypothesis is
that PT is responsible for Bp induced cough. Previous research has shown that SpragueDawley rats IB challenged with a PT -/- Bp strain did not cough (7). Furthermore, avirulent
phase 4 strain of Bp, which does not release PT, also did not induce cough as well (7).
Another potential hypothesis that needs to be investigated is that Bp induced cough is
activated through the increased production of bradykinin (20). Bradykinin is a proinflammatory hormone that can cause blood vessel dilation and smooth muscle
contraction (21). Several studies have shown that bradykinin mediated activation of
respiratory nerves have been shown to induce cough (22–25). Aerosol inoculation of
bradykinin induced cough in guinea pigs (26). Both PT and ACT could potentially play a
role in GPCRs regulation of bradykinin activation and the induction of cough (27). IN
inoculation of PT and ACT Bp mutants and the measurement of cough would begin to
answer these toxins’ role in cough. Also, with the emergence of genetically diverging
strains, it is currently unknown how genetic divergence effects disease severity, notably
Bp induced cough. Vaccination and challenge studies utilizing current isolates will be
critical in the assessment of vaccine efficacy in the next generation of pertussis vaccines.

4.4 Bordetella bronchiseptica and Bordetella parapertussis challenge experiments
in rats
Limited research has been conducted in investigating both the pathogenesis and
mechanism of cough involving Bordetella bronchiseptica and Bordetella parapertussis
infected rats. Bordetella parapertussis is a human pathogen that can also cause
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whooping cough disease, while Bordetella bronchiseptica is the causative agent of kennel
cough in animals (28). All Bordetella species release ACT; however, Bp is the only
Bordetella species to produce PT (11). Interestingly, IB challenge with Bordetella
parapertussis in rats did not result in cough, which was measured via sound activated
video cameras (7). More recently, identification of the anti-sigma factor BspR/BtrA of
Bordetella bronchiseptica was shown to play a role in the regulation of bacterial factors
involved in cough (8). IN inoculation of a Bordetella bronchiseptica BspR/BtrA mutant
exhibited reduction of cough (8). Research has demonstrated that bspR negatively
regulates the expression of the type III secretion system, and deletion in bspR results in
both the increased expression and release of type III secretion system effector molecules
(29–31). However, the factors released that elicit coughing manifestation have yet to be
identified (8). Bordetella bronchiseptica and Bordetella parapertussis challenge studies
utilizing the coughing rat model-- detailed in chapter 2-- would provide further insight into
the pathogenesis and potentially identify cough factors of these two strains. Furthermore,
the rat model could serve as a preclinical model to evaluate vaccine efficacy against
Bordetella bronchiseptica and Bordetella parapertussis. While vaccines are available for
kennel cough, many questions regarding protection against cough, vaccine mediated
immunity, and detailed systemic and mucosal serological responses induced through
immunization, remained unanswered (32).

4.5 Lessons learned from mucosal immunity
Chapter 3 utilizes the coughing rat model of pertussis to evaluate vaccine efficacy from
mucosal immunization of DTaP against a clinically relevant strain of Bp, D420. We
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investigated vaccine efficacy of both intranasal and oral immunization of DTaP compared
to the positive vaccine controls, IM administration of DTP and DTaP. This is the first study
to investigate mucosal immunization of DTaP in the coughing rat model of pertussis. Here
we evaluated vaccine mediated protection against Bp elicited cough, bacterial burden,
bronchiole constriction, pulmonary inflammation as well as the generated serological and
cytokine responses (Table 2).
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Serological response

IM-wP

Bp-IgG/PT-IgM/PTIgG

IM-aP

Bp-IgG/PT-IgG

Bp-IgG/PT-IgM/PTIgG

IN-aP

MVC

Bp-IgM/Bp-IgG

Bp-IgG/PT-IgG

Time

Bp-IgG

1-week p.b

2-week p.p

1-week p.p

Day 1

IL-13

Bp-IgG/PT-IgM/PTIgG/Bp-IgA

IL-17

IL-17

IL-12

IFN-!

Bp-IgG/PT-IgM/PTIgG

G-CSF

Bp-IgG

Days 1-9

IL-17

TNF-!
TNF-!

Day 9
Protection against cough

Days 1-9

Day 9

Day 1

Day 9

Day 1

Protection against bronchiole
constriction
Cytokine response

Protection against bacterial
burden in the respiratory
tract

OG-aP

Bp-IgG/Bp-IgA

Table 3. Summary of vaccine mediated immune responses following Bp challenge in the coughing rat model
of pertussis.
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To date, only two studies have reported evaluating vaccine mediated protection against
cough from DTaP and DTP vaccines in the rat model of pertussis (6, 7). In 1998, Hall et
al demonstrated that both a 3 component (PT, FHA, and PRN) and 5 component (PT,
FHA, PRN, and Fim 2/3) aP vaccines could decrease cough count following Bp challenge
(6). IP immunization of DTP was also capable of protecting against Bp induced cough (7).
Cough was counted using audio tape recorders. Protection against Bp colonization of the
respiratory tract was not reported following vaccination and challenge. In our current
study, we utilized WBP to measure coughs and bronchiole restriction from Bp infection.
Our data demonstrated that both IN-aP and OG-aP vaccinated rats were protected
against Bp induced cough (Chapter 3. Fig. 16). In addition to protection against cough,
mucosal vaccinated rats were also protected against bacterial burden in the nasal cavity,
trachea, and lung (Chapter 3. Fig. 21). In addition, IN-aP vaccinated rats protected
against bronchiole constriction (Chapter 3. Fig. 16). In both previous studies, a total of
1 human dose of aP and DTP was administered before Bp challenge (6, 7). In chapter 3,
we administered 1/5th a human dose of DTP or DTaP to prime and boost. 1/5th human
dose was selected in efforts to try and relatively compare size differences between rats
and mice. 1/40th human dose is protective against Bp colonization in mice, and rats are
approximately 10X the size of mice (33). Other human-rat-titrations need to be explored.
Finding a minimally protective dose of current DTaP would allow for proper evaluation of
the addition of new vaccine antigens to DTaP or potential new adjuvants. Use of a high
vaccine dose would potentially “mask” the protective capabilities of new antigen or
adjuvant, as the vaccine mediated immune response would already be saturated.
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4.6 Mucosal immunity
Mucosal immunization has been of interest in the pertussis field. Bp is strictly a mucosal
pathogen, and dissemination of Bp is rare (34, 35). This makes generating an immune
response at the site on infection critical to protection against pertussis. Intranasal
vaccination route has been investigated as a potential vaccination strategy to generate a
protective mucosal immune response. Studies performed in our lab and others have
investigated IN DTaP vaccination in mice (36–40). IN vaccination of DTaP induced both
antigen specific systemic and mucosal antibody titers to Bp (36, 37). IN vaccination of live
attenuated strain BPZE1 has also shown to be protective in mice, baboons, and humans
in phase 2 clinical trials (41–44). The observed protection is through the induction of both
serum and mucosal IgG and IgA antibodies respectively, and the generation of tissue
resident memory T cells (Trms) (41, 45). Oral vaccination of heat inactivated Bp resulted
in both systemic and mucosal antibody titers in newborns (46). Mice orally vaccinated
with Salmonella strains harboring Bp antigens, such as PRN and FHA, have resulted in
decrease in bacterial colonization in the lung, and resulted in antibody titers both
systemically and in the gut (47, 48). In rats, both IN and OG vaccination induced mucosal
and systemic Bp specific antibody titers (Chapter 3. Fig. 15, 18, 19). Antigen specific B
cells were also observed following mucosal vaccination of DTaP in the bone marrow
following Bp challenge (Chapter 3. Fig. S15). Our data supported that mucosal
vaccination for pertussis can induce both systemic and mucosal antibody titers that
correlate to the observed decrease in bacterial burden. Future studies investigating T cell
responses in the coughing rat model of pertussis are needed to illustrate the full protective
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immune response induced from IN and OG vaccination. As discussed in chapter 1, T cell
immune responses are critical in observed protection from natural immunity and mucosal
vaccination.

4.7 Improvements to DTaP/Tdap
Since the introduction of DTaP, we have observed cyclic increases in the number of
pertussis cases (49, 50). Since the resurgence of pertussis, improvements to the current
vaccine are critical. Potential strategies include correcting antigenic sin of current DTaP
vaccinated populations, use of different adjuvants and investigation of new potential
vaccine antigens.

A previous report has shown that with DTaP and DTP vaccination in humans, there is a
significant decrease in antibody responses to ACT compared to convalescent individuals
after Bp infection (51). It has been hypothesized that this decrease in antibody response
could be due to original antigenic sin (51). Antigenic sin describes the tendency of the
immune response to utilize the immunity generated upon vaccination or previous infection
upon subsequent infection. This “locks” the immune response and prevents any additional
protective immunity. With the emergence of genetically divergent strains, it is important
to shift from a Th2 dominant response that is generated from DTaP vaccination. One
potential approach to improve the diversity of the generated vaccine immune response is
through a mucosal booster vaccine. IM-aP immunization will induce systemic immunity
which we hypothesize will be re-focused to the mucosa by delivery of DTaP by intranasal
and/or oral vaccination (Figure 24).
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A

B

C

Figure 24. Vaccine generated immune responses from intramuscular and
mucosal immunization of DTaP, and booster immunization of DTaP. (A) IM
vaccination of DTaP induces T cell differentiation of naïve T cells to Th2 cells.
Antigen-specific B cells produce IgG4 antibodies, which protect against PT toxin
that is released systemically. The generated immune responses are not recruited
to the mucosa, where Bp colonization occurs. (B) Mucosal immunization
generates both a systemic and mucosal immune response. Following mucosal
immunization induces T cell differentiation of naïve T cells to Th1 and Th17 cells,
resulting in the production of IFN-𝛾 and IL-17 at the mucosa. IgG1 antibodies are
produced from antigen-specific B cells as well as secretory IgA antibodies. (C) IM
prime vaccination of DTaP followed by mucosal vaccination could potentially
rescue against antigenic sin from repeated IM vaccination of DTaP. Adapted from
(Chasaide, 2020). Created with Biorender.com
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Another potential solution to combat the pertussis problem, is the addition of new vaccine
antigens. As described in chapter 1, Bp is evolving to no longer express particular
antigens in DTaP, such as PRN (52). Strains lacking PT have also been reported (53).
Virulence factor ACT is a potential candidate to be included in the next generation
pertussis vaccine. ACT is a virulence factor that plays a role in Bp persistence by inhibiting
innate immune responses to Bp killing (54). Convalescent patients who have cleared Bp
infection have ACT antibodies in their serum, and in murine studies, immunization of ACT
has been protective (55). RTX region of ACT has also been shown to induce a serological
response to ACT and be protective (33). Vaccination with Bordetella resistance to killing
A (BrkA) has been shown to reduce bacterial colonization in mice following Bp challenge
(56). Vaccination with autotransporters Vag8 and SphB1 have been demonstrated to
decrease bacterial burden in the lung; however, did not in the upper respiratory tract (57).
Protection against hallmark symptom of pertussis, paroxysmal cough has yet to be
evaluated utilizing these antigens. The rat model of pertussis could provide a preclinical
model to evaluate the vaccine mediated efficacy with the addition of these antigens and
their protective responses against Bp induced cough.

The adjuvant that is currently used in DTaP is alum. Alum works by promoting strong Th2
immune responses; however, studies have shown that the optimal long-lived immune
responses generated from natural infection and DTP vaccination induces Th1/Th17
immune responses (58). Adjuvants capable of generating Th1/Th17 immune responses
are being explored. Vaccination with TLR4 agonists such as monophosphoryl lipid-A
(MPLA) in combination with DTaP decreased bacterial burden in the lung of Bp challenge
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mice (59). TLR9 agonist, unmethylated single-stranded CpG, increased anti-PT IgG
antibody titers upon combination and vaccination with DTaP (60). CpG also stimulated a
protectiveTh1/Th17 immune response following vaccination that protected against Bp
colonization in the lung following challenge (60). Stimulator of interferon genes (STING)
agonists have also protected against bacterial burden in the lung (61). Future studies
evaluating bacterial clearance from the upper respiratory tract and protecting against
cough are needed to further differentiate the ideal adjuvant for the next generation of
pertussis vaccines.

4.8 Improvement of oral vaccination against pertussis
In chapter 3, we illustrated that oral vaccination of DTaP protected against Bp induced
cough and Bp colonization in the nasal cavity, trachea, and lung post-challenge in the
coughing rat model of pertussis (Chapter 3. Fig. 16, 21). The generation of antibody titers
to Bp were not detected until day 9 post-challenge. A proposed mechanism can be seen
in chapter 3 (Fig. S20). A possible hypothesis for this observed delay in the generation
of antibody titers is that limited availability of antigen travels to the GALT. Vaccines
delivered orally rely on antigens traveling through the acidic environment of the stomach
before arriving at the GALT (62). Potential strategies to correct this delay in vaccine
mediated immune responses include an overall increase in the antigen concentration
delivered, an increase in the number of vaccine doses, or finding delivery mechanism to
increase antigen presentation to the GALT. Research has shown that targeting antigens
to M cells has increased vaccine efficacy (63, 64). Use of viral-like particles and vesicles
containing vaccine antigens have increased antigen uptake by M cells (63, 64). Addition
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of cytokines IL-12, GM-CSF, and TLR agonists have been shown to increase the overall
immune response generated from oral vaccination (65–67)
4.9 Experimental oral vaccines of potential
Oral vaccination has been briefly explored as a potential route of immunization against
pertussis. Newborns orally vaccinated with wP induced the production of both systemic
and mucosal antibodies to Bp (68). Oral vaccination of killed Bp also resulted in systemic
and mucosal antibody titers in both the serum and saliva of newborns (69). Further,
vaccinated newborns had a lower incidence of pertussis in the first year of life compared
to unvaccinated newborns (69). Studies in mice have also shown that oral immunization
of bacterial vectors harboring Bp virulence factors resulted systemic and mucosal
serological responses (70). In chapter 3, OG vaccination of DTaP resulted in protection
against bacterial burden and Bp induced cough; however, OG vaccination did not protect
against bronchiole constriction and the generation of systemic antibody titers were not
significantly increased compared to mock vaccinated challenge rats until day 9 postchallenge (Chapter 3. Fig. 17-18). Several approaches could be taken to further increase
vaccine efficacy of an oral vaccine, such as encapsulation of antigens or antigen targeted
delivery to M cells (71). Lipid-based vehicles, such as liposomes and bilosomes, are the
most commonly used vehicles for encasing and delivery of vaccine antigens (71).
Hydrophilic proteins and/or peptides can be encased inside the vesicle, while hydrophobic
components can be included in the outer layers (72, 73). Encapsulation of antigens in
lipid based vehicles further protect the antigens from the acidic pH of the gut and other
proteolytic enzymes (71). Additionally, lectin coated liposomes were capable of targeting
antigens to M cells, increasing the mucosal serological responses (72, 74). Nanoparticles
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and polymeric microparticles can also be used to encapsulate and deliver antigens to the
gut-associated lymphoid tissue (75–77). Oral immunization of particles encapsulated with
the lectins Ulex europaeus agglutinin-1 and Aleuria auranitia increased mucosal IgA
antibody titers and induced a IL-2 and IFN-γ Th1 mediated immune response (74, 78–
80). Taken together, these data show potential approaches that could be taken to further
increase vaccine mediated immunity induced from an oral vaccine against pertussis.

4.10 In summary
The coughing rat model of pertussis can be used as a model to not only study Bp
pathogenesis and potentially the mechanisms behind paroxysmal cough, but also be
used as a preclinical model for the evaluation of the “next generation” of pertussis
vaccines. Utilizing the coughing rat model of pertussis, we have demonstrated that both
intranasal and oral vaccination of DTaP can be protective against Bp induced cough and
overall, we have optimized the coughing rat model to study the next generation of
pertussis vaccines
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